var title_f17_34_17952="Echogenic bowel cystic fibrosis";
var content_f17_34_17952=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F64460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F64460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Echogenic bowel, cystic fibrosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 407px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In this longitudinal image, there is a very echogenic portion of fetal bowel seen in the mid abdomen that is as echodense as fetal bone. Both parents were known carriers of the &Delta;F508 cystic fibrosis mutation, and the newborn was found to be homozygous for this mutation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen Chasen, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17952=[""].join("\n");
var outline_f17_34_17952=null;
var title_f17_34_17953="Intradermal cyst injection";
var content_f17_34_17953=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F75695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F75695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intradermal injection of inflamed acne cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 355px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17953=[""].join("\n");
var outline_f17_34_17953=null;
var title_f17_34_17954="Classification of endometriosis";
var content_f17_34_17954=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F66366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F66366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Examples of the classification of endometriosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 441px; height: 305px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from the American Society for Reproductive Medicine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17954=[""].join("\n");
var outline_f17_34_17954=null;
var title_f17_34_17955="Acute lymphoblastic leukemia (ALL) treatment in adults";
var content_f17_34_17955=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Acute lymphoblastic leukemia (ALL) treatment in adults (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/34/17955/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17955/contributors\" id=\"au3198\">",
"       Richard A Larson, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/34/17955/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17955/contributors\" id=\"se407\">",
"       Bob Lowenberg, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?17/34/17955/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17955/contributors\" id=\"de1889\">",
"       Rebecca F Connor, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?17/34/17955?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      ACUTE LYMPHOBLASTIC LEUKEMIA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Acute lymphoblastic leukemia (ALL) is a cancer of blood cells. ALL is also known as lymphoblastic lymphoma when the disease primarily involves lymph nodes rather than the blood and bone marrow. ALL involves a type of white blood cell called a lymphocyte. Acute means that it develops and advances quickly, and requires immediate treatment.",
"    </p>",
"    <p>",
"     Normally, lymphocytes and other blood cells are produced by the bone marrow (the spongy area in the middle of bones) in a controlled fashion. In someone with ALL, this process is abnormal. Large numbers of immature and abnormal lymphocytes (lymphoblasts) are produced and released into the blood stream. In their immature state, these cells cannot perform their usual functions, leaving the person vulnerable to anemia, infection, and bleeding.",
"    </p>",
"    <p>",
"     The overproduction of lymphoblasts prevents the bone marrow from producing other important blood cells, including red blood cells, other types of white blood cells (especially neutrophils, sometimes called \"polys\"), and platelets. The lymphoblasts can collect in certain areas of the body, such as the brain, spinal cord, and lymph nodes (glands).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      GENERAL INFORMATION ABOUT ALL TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     A number of medications, or chemotherapy agents, are known to be effective against ALL. However, the best combination of medicines or the best treatment schedule is still not known. Because there are so many different medicines, dosing schedules, and combinations, it has been difficult to study any one component of treatment thoroughly.",
"    </p>",
"    <p>",
"     However, general principles of treatment have emerged and are followed in most cancer treatment centers. The exact regimens may vary from one center to another. Regimens can also vary based upon individual characteristics such as your age, the total number of white blood cells, or characteristics of the genetic changes. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"      \"Cytogenetics in acute lymphoblastic leukemia\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Treatment side effects",
"     </span>",
"     &nbsp;&mdash;&nbsp;Side effects of treatment will depend on the actual medicines being used, the schedule of treatment, and other factors. Many of the chemotherapy medicines used to treat ALL share common side effects such as hair loss (which is temporary), nausea and vomiting, mouth sores, diarrhea or constipation, and an increased risk of infections and bleeding. Treatment to minimize these side effects is available.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Phases of treatment",
"     </span>",
"     &nbsp;&mdash;&nbsp;The usual treatment for ALL can be divided into three phases: induction of remission,",
"     <span class=\"nowrap\">",
"      consolidation/intensification",
"     </span>",
"     of therapy, and remission maintenance (also called continuation therapy). A summary of one regimen&rsquo;s entire treatment process is available in the table (",
"     <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Treatment of high-risk disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;Patients with high risk disease, including those with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia and Burkitt",
"     <span class=\"nowrap\">",
"      leukemia/lymphoma,",
"     </span>",
"     require special treatment programs that use different medications and doses from those used in patients with standard risk ALL. In addition, allogeneic stem cell transplantation is more frequently recommended in those patients with Ph+ ALL.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H6\">",
"     <span class=\"h1\">",
"      INDUCTION OF REMISSION",
"     </span>",
"    </p>",
"    <p>",
"     Induction of remission takes about four weeks and is almost always performed while the patient remains in the hospital. Treatment includes: vincristine (Oncovin) and an anthracycline (such as daunorubicin or doxorubicin) along with prednisone, dexamethasone, or another steroid hormone (",
"     <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"      table 1",
"     </a>",
"     ). Patients with Philadelphia chromosome positive ALL require the addition of a BCR-ABL tyrosine kinase inhibitor, such as imatinib or dasatinib. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"      \"Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Vincristine and the anthracycline drugs are anti-cancer chemotherapy drugs. These drugs work by interfering with the ability of rapidly growing cells (such as cancer cells) to divide or reproduce themselves. Because most of an adult's normal cells are not actively growing, they are less affected by chemotherapy, with the exception of bone marrow (where the blood cells are produced), the hair, and the cells lining the gastrointestinal tract.",
"    </p>",
"    <p>",
"     Effects of chemotherapy on these and other normal tissues cause side effects during treatment, including anemia (lowered red blood cell count), an increased risk of infection (lowered white blood cell count), and bleeding (lowered platelet count).",
"    </p>",
"    <p>",
"     Vincristine and the anthracycline drugs are given through an intravenous (IV) line. Prednisone or dexamethasone can be given either by mouth or IV. Other medicines such as cyclophosphamide (Cytoxan, given IV) or L-asparaginase (Elspar, given as a subcutaneous, intramuscular or IV injection) may also be given.",
"    </p>",
"    <p>",
"     Approximately 80 percent of newly diagnosed adults with ALL enter complete remission after the initial treatment, meaning that there are no detectable lymphoblasts in the blood or bone marrow and that the bone marrow is functioning normally. However, such remissions are usually short-lived unless additional chemotherapy is given (see",
"     <a class=\"local\" href=\"#H7\">",
"      'Consolidation/intensification therapy'",
"     </a>",
"     below).",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H7\">",
"     <span class=\"h1\">",
"      CONSOLIDATION/INTENSIFICATION THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Once remission is achieved, additional therapy is needed to avoid relapse. Relapse probably occurs because abnormal cells are still present, even though these cells cannot be detected by routine examination of the blood or bone marrow. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"      \"Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Chemotherapy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Some of the same medicines given during induction are also used during remission consolidation therapy, which may last for several months. Most of this treatment can take place during the day, without the need to remain in the hospital overnight (",
"     <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     In addition to scheduled doses of chemotherapy, many treatment programs call for preventive treatment of the central nervous system (the brain and spinal cord). Abnormal lymphoblasts in the brain often do not respond to chemotherapy given only into a vein, but must be treated directly with radiation to the head",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     injection of chemotherapy, such as methotrexate, into the fluid surrounding the spinal cord and brain through a lumbar puncture (also called a spinal tap).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Stem cell transplantation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Stem cell transplantation, also called bone marrow transplantation or hematopoietic stem cell transplantation, is a treatment in which the patient is given very high doses of chemotherapy or total body irradiation (TBI), called myeloablative treatment. This kills cancer cells but also destroys all normal cells developing in the bone marrow. This means that the body's normal source of blood cells (the bone marrow) is no longer functional. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"      \"General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     After the treatment, the patient requires a supply of healthy young blood cells (called stem cells) to be reintroduced, or transplanted. This is done by a transfusion of blood stem cells from a healthy well-matched donor. The transplanted cells re-establish the blood cell production process in the bone marrow. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      \"Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Current data indicate that there is no clear advantage to stem cell transplantation as compared with chemotherapy during consolidation therapy for standard risk patients in their first complete remission, although it may shorten the overall treatment course. However, allogeneic stem cell transplantation is recommended, if necessary, following a relapse when patients are in a second complete remission, and for subsets of patients with more aggressive forms of ALL in first remission.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       <strong>",
"        Allogeneic",
"       </strong>",
"       transplantation uses stem cells from a donor other than the patient, ideally a sibling with a similar genetic makeup (called a matched related donor, or MRD). If the patient does not have a sibling with similar genetic characteristics, an unrelated person with a similar genetic makeup may be used (called a matched unrelated donor, or MUD). Another possibility is to use a sibling with partially similar genetic characteristics, although this is not as well studied (sometimes called a partially matched family member donor). Umbilical cord blood can also provide a source of unrelated stem cells.",
"       <br/>",
"       <br/>",
"       Allogeneic transplantation treats ALL in two ways. First, high doses of chemotherapy or total body irradiation are given immediately before the transplant, which aggressively attacks and kills the leukemia cells present in the blood and bone marrow. Second, when cells from another person are transfused, some of the donor stem cells mature into immune cells, and these donor immune cells can cause an immune response that helps destroy any remaining leukemia cells. This is called the \"",
"       <strong>",
"        graft versus leukemia",
"       </strong>",
"       \" or \"graft versus tumor\" effect. Unfortunately, this response is closely associated with a complication called \"",
"       <strong>",
"        graft versus host disease",
"       </strong>",
"       \" in which the immune response includes an attack on some of the patient's own healthy organs. Symptoms can include severe skin rash, diarrhea, liver damage, and other problems. Still, allogeneic transplantation is preferred over autologous transplantation in patients with ALL.",
"      </li>",
"      <li>",
"       <strong>",
"        Autologous",
"       </strong>",
"       transplantation, which uses the patient's own stem cells collected while the patient is in complete remission, is of no greater benefit than chemotherapy for adults with ALL. Thus, it is generally not recommended.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H10\">",
"     <span class=\"h1\">",
"      MAINTENANCE THERAPY",
"     </span>",
"    </p>",
"    <p>",
"     Remission maintenance therapy or remission continuation therapy is a standard part of ALL treatment, although research studies have not clearly shown its benefit for adults. It is also unclear how long therapy should continue. Depending upon the program chosen, treatment is often continued for three years (",
"     <a class=\"graphic graphic_table graphicRef67471 \" href=\"UTD.htm?12/56/13198\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     During maintenance treatment, oral medications (pills) are taken on certain days of the month and intravenous (IV) chemotherapy may be given into a vein once per month. Side effects during this phase of treatment are less frequent and less severe than those experienced during earlier stages of treatment. Most people are able to return to full activity during their maintenance treatment period.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H11\">",
"     <span class=\"h1\">",
"      RESIDUAL DISEASE AND RELAPSE RISK",
"     </span>",
"    </p>",
"    <p>",
"     Following the standard two to three years of treatment, patients in complete clinical remission should have a bone marrow aspiration and biopsy repeated every three to six months for at least the next two years. This allows for early detection and treatment if relapse were to occur. Patients with ALL who maintain complete, continuous remission for four to five years are considered cured and no longer need routine bone marrow examination. However, relapses of ALL as long as 21 years after diagnosis have been reported.",
"    </p>",
"    <p>",
"     Unfortunately, up to 25 percent of adults with ALL have disease that is resistant to the initial induction of remission. In addition, many adults with ALL who do attain an initial complete remission will ultimately suffer a relapse. Although a second remission can often be achieved, re-treatment of such patients is generally unsuccessful in the long run, and most will die of their disease or of complications of treatment. Allogeneic transplantation is generally recommended for patients who attain a second remission.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Treatment of relapse or resistant disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;A second remission may be attained using a similar induction regimen if the relapse occurs more than two years following initial treatment. However, this approach is not recommended if a patient has primary resistant disease (complete remission was never attained) or for those who relapse while receiving induction or maintenance therapy. (See",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link\">",
"      \"Treatment of relapsed or refractory acute lymphoblastic leukemia in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Salvage regimens are also called rescue treatments and are used after standard frontline treatments have failed. These regimens are designed to reduce symptoms and prolong survival, but may not be able to cure the disease. Optimally, patients should enroll onto a clinical trial specifically designed for treatment of resistant or relapsed ALL so they can get access to new agents given either alone or in combination.",
"    </p>",
"    <p>",
"     Allogeneic stem cell transplantation is also a reasonable option for selected patients with resistant or relapsed disease. All eligible patients who achieve a second complete remission should consider allogeneic stem cell transplantation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      CLINICAL TRIALS",
"     </span>",
"    </p>",
"    <p>",
"     Many patients with leukemia will be asked to enroll on a clinical research trial. A clinical trial is a controlled way to study the effectiveness of new treatments or new combinations of known therapies. They are carefully designed and reviewed by experts in the field to provide state-of-the-art care for individual patients as well as to improve the outcomes of patients overall. Additional information concerning clinical trials for ALL can be obtained from the treatment team or the following websites:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       <a class=\"external\" href=\"file://www.cancer.gov/clinicaltrials\">",
"        www.cancer.gov/clinicaltrials",
"       </a>",
"      </li>",
"      <li>",
"       <a class=\"external\" href=\"file://clinicaltrials.gov/\">",
"        file://clinicaltrials.gov",
"       </a>",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H14\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864597632\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027149\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?15/15/15602?source=see_link\">",
"      Patient information: Acute lymphoblastic leukemia (ALL) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?37/13/38098?source=see_link\">",
"      Patient information: Leukemia in adults (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12027175\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?34/4/34886?source=see_link\">",
"      Patient information: Bone marrow transplantation (stem cell transplantation) (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H864597639\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/25/26007?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor B cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/20/30023?source=see_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of precursor T cell acute lymphoblastic leukemia/lymphoma",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/25/22938?source=see_link\">",
"      Cytogenetics in acute lymphoblastic leukemia",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/11/9400?source=see_link\">",
"      General principles of hematopoietic cell transplantation for acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/15/21753?source=see_link\">",
"      Treatment of relapsed or refractory acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/5/23642?source=see_link\">",
"      Induction therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/15/39161?source=see_link\">",
"      Post-remission therapy for Philadelphia chromosome negative acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44489?source=see_link\">",
"      Induction therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/26/3497?source=see_link\">",
"      Post-remission therapy for Philadelphia chromosome positive acute lymphoblastic leukemia in adults",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Cancer Institute",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.gov/cancertopics\">",
"        www.cancer.gov/cancertopics",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       American Cancer Society",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.org/\">",
"        www.cancer.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Leukemia &amp; Lymphoma Society",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.leukemia-lymphoma.org/hm_lls\">",
"        www.leukemia-lymphoma.org/hm_lls",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       National Marrow Donor Program",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.marrow.org/\">",
"        www.marrow.org",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The American Society of Clinical Oncology",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.cancer.net/portal/site/patient\">",
"        www.cancer.net/portal/site/patient",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?17/34/17955/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 2, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?17/34/17955?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17955/abstract/1\">",
"      G&ouml;kbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Semin Hematol 2009; 46:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17955/abstract/2\">",
"      Khaled SK, Thomas SH, Forman SJ. Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults. Curr Opin Oncol 2012; 24:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17955/abstract/3\">",
"      Fielding AK. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2011; 2011:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17955/abstract/4\">",
"      Fielding AK. Current therapeutic strategies in adult acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2011; 25:1255.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f17_34_17955=[""].join("\n");
var outline_f17_34_17955=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           ACUTE LYMPHOBLASTIC LEUKEMIA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           GENERAL INFORMATION ABOUT ALL TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H6\">",
"           INDUCTION OF REMISSION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H7\">",
"           CONSOLIDATION/INTENSIFICATION THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H10\">",
"           MAINTENANCE THERAPY",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H11\">",
"           RESIDUAL DISEASE AND RELAPSE RISK",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           CLINICAL TRIALS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H14\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"UTD.htm?12/56/13198\" title=\"table 1\">",
"           CALGB regimen ALL adults",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f17_34_17956="Neonatal lupus erythematosus";
var content_f17_34_17956=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F51166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F51166&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Neonatal lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Annular erythematous thin plaques are present on the head.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17956=[""].join("\n");
var outline_f17_34_17956=null;
var title_f17_34_17957="Vancomycin: Patient drug information";
var content_f17_34_17957=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Vancomycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=see_link\">",
"     see \"Vancomycin: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=see_link\">",
"     see \"Vancomycin: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vancocin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      PMS-Vancomycin;",
"     </li>",
"     <li>",
"      Sterile Vancomycin Hydrochloride, USP;",
"     </li>",
"     <li>",
"      Val-Vancomycin;",
"     </li>",
"     <li>",
"      Vancocin&reg;;",
"     </li>",
"     <li>",
"      Vancomycin Hydrochloride for Injection, USP",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015675\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691487",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to vancomycin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have hearing loss.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015679\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698647",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       During the infusion, a rash on the face, neck, trunk, and arms.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699001",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Ringing in ears.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698616",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in hearing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705324",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         All products:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696012",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as an infusion into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695961",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be given at home.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696361",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Your doctor may teach you how to give this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696118",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Throw away needles in a needle/sharp disposal box and take the box back to your doctor when it is full.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695913",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10015678\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696583",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10015683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Capsule:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2696421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Liquid:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699335",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature or in a refrigerator. Do not freeze.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3772542",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored at room temperature, throw away any part not used after 26 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3772543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If stored in the refrigerator, throw away any part not used after 75 days.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699416",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store shot as you have been told by the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11281 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17957=[""].join("\n");
var outline_f17_34_17957=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233330\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233331\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015675\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015674\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015679\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015680\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015682\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015677\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015678\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015683\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015684\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?41/41/42649?source=related_link\">",
"      Vancomycin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/58/23465?source=related_link\">",
"      Vancomycin: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_34_17958="Blastocystis microscopy";
var content_f17_34_17958=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F73525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F73525&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blastocystis microscopy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 584px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A, B)",
"    <em>",
"     Blastocystis",
"    </em>",
"    spp cyst-like forms stained in trichrome. The nuclei in the peripheral cytoplasmic rim are visible, staining purple.",
"    <br/>",
"    (C, D)",
"    <em>",
"     Blastocystis",
"    </em>",
"    spp cyst-like forms in a wet mount stained in iodine.",
"    <br/>",
"    (E)",
"    <em>",
"     Blastocystis",
"    </em>",
"    spp cyst-like form in a wet mount, unstained.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Centers for Disease Control and Prevention. Parasites and Health: Blastocystis hominis infection. Available at:",
"     <a href=\"file://www.dpd.cdc.gov/dpdx/html/Blastocystis.htm\" target=\"_blank\">",
"      file://www.dpd.cdc.gov/dpdx/html/Blastocystis.htm",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17958=[""].join("\n");
var outline_f17_34_17958=null;
var title_f17_34_17959="Clinical implications and treatment of left ventricular hypertrophy in hypertension";
var content_f17_34_17959=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical implications and treatment of left ventricular hypertrophy in hypertension",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17959/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17959/contributors\">",
"     Norman M Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17959/contributors\">",
"     Pamela S Douglas, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17959/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17959/contributors\">",
"     George L Bakris, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17959/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17959/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/34/17959/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Left ventricular hypertrophy (LVH) is a common finding in patients with hypertension and can be diagnosed either by ECG or by echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/1\">",
"     1",
"    </a>",
"    ]. The latter is the procedure of choice, since the sensitivity of the different ECG criteria may be as low as 7 to 35 percent with mild LVH and only 10 to 50 percent with moderate to severe disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/2\">",
"     2",
"    </a>",
"    ]. Nevertheless, if echocardiography is unavailable or too expensive, appropriate ECG criteria can be used to detect increased LV mass [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical implications and therapy of LVH in hypertension will be reviewed here. The definition and pathogenesis of this complication in hypertensive patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LVH AND INCREASED CARDIOVASCULAR RISK",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of LVH (on ECG or echocardiography) is important clinically because it is associated with increases in the incidence of heart failure, ventricular arrhythmias, death following myocardial infarction, decreased LV ejection fraction, sudden cardiac death, aortic root dilation, and a cerebrovascular event.",
"   </p>",
"   <p>",
"    LVH diagnosed by echocardiography, which is much more sensitive than the ECG, also carries an increased risk for cardiac events (angina and myocardial infarction, heart failure, and serious ventricular arrhythmia), stroke, and cardiovascular deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. Furthermore, the increase in cardiovascular risk is directly related to the degree of increase in left ventricular mass (",
"    <a class=\"graphic graphic_figure graphicRef52329 \" href=\"UTD.htm?24/36/25165\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50941 \" href=\"UTD.htm?17/2/17449\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/4,6-8\">",
"     4,6-8",
"    </a>",
"    ], an effect that is independent of blood pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The range of findings is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study, 1033 subjects over the age of 50 with essential hypertension and no previous cardiovascular events were followed for a median of three years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/6\">",
"       6",
"      </a>",
"      ]. The rate of major cardiovascular events (fatal and nonfatal MI; all-cause, sudden, or cardiovascular mortality; severe heart failure; or severe renal failure requiring dialysis) was significantly higher in the 29 percent of patients with an increased left ventricular mass, defined as &ge;125",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      body surface area (3.2 versus 1.3 per 100 patient years with normal mass). After adjustment for other risk factors, LVH was associated with an increase in cardiovascular events (relative risk 2.08); for each 39",
"      <span class=\"nowrap\">",
"       g/m2",
"      </span>",
"      increase in left ventricular mass, there was a 40 percent increased risk of a major cardiovascular event (",
"      <a class=\"graphic graphic_figure graphicRef50941 \" href=\"UTD.htm?17/2/17449\">",
"       figure 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      A report from the Framingham Heart Study examined the relationship between left ventricular mass and hypertrophy and sudden death in 3661 subjects over the age of 40 who were followed for 14 years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/7\">",
"       7",
"      </a>",
"      ]. The prevalence of left ventricular hypertrophy was 22 percent and the risk factor adjusted hazard ratio for sudden death was 2.16 (p = 0.008). For each 50",
"      <span class=\"nowrap\">",
"       g/m",
"      </span>",
"      increment in left ventricular mass, the risk-factor adjusted hazard ratio for sudden death was 1.45 (p = 0.008) (",
"      <a class=\"graphic graphic_figure graphicRef66486 \" href=\"UTD.htm?18/35/19005\">",
"       figure 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The cardiovascular risk associated with LVH can be reduced by effective antihypertensive therapy that leads to regression of LVH. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Reduction in cardiovascular risk'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanisms for increased risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The increased cardiac risk associated with LVH is probably due in part to myocardial ischemia that can be induced by a variety of factors. In hypertrophied myocardium, there is a reduced density of capillaries. Furthermore, the enlarged muscle mass limits the ability of the coronary arteries to dilate in response to decreased perfusion or during vasodilatory stress [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/11\">",
"     11",
"    </a>",
"    ]; it may also directly compress the endocardial capillaries. Both of these factors can decrease coronary reserve and can have a number of important clinical implications.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coronary occlusion is associated with a greater degree of infarction and a higher mortality rate than seen in the absence of LVH [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The hypertrophied myocardium may be more susceptible than normal myocardium to the effects of ischemia. In a study of patients with sudden cardiac death, the patients with hypertension and LVH who died suddenly had less extensive coronary disease and were less likely to have thrombi in the coronary vessels than normotensives who died suddenly [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The development of heart failure with LVH results from depressed left ventricular systolic function",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    diastolic dysfunction. The deleterious effect of left ventricular remodeling may be an important determinant of progression to overt heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/14\">",
"     14",
"    </a>",
"    ]. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=see_link\">",
"     \"Pathophysiology of diastolic heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=see_link\">",
"     \"Cardiac remodeling: Basic aspects\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LVH also causes several electrophysiologic changes or electrical remodeling, including nonuniform action potential prolongation, altered repolarization and increased dispersion of recovery, and the easily provocable early afterpotentials, which are associated with increased vulnerability to atrial fibrillation, ventricular arrhythmias, especially torsades de pointes, and sudden death [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFECT OF ANTIHYPERTENSIVE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, lowering the BP with antihypertensive agents, weight loss, or dietary sodium restriction decreases cardiac mass in patients with LVH, including patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Regression of LVH is related both to the antihypertensive response and, to some degree, to the type of therapy used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Choice of drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression of LVH over a period of a few months has been reported with angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), the direct renin inhibitor,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"     aliskiren",
"    </a>",
"    , some calcium channel blockers (particularly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"     diltiazem",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ), and some sympatholytic agents (including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"     methyldopa",
"    </a>",
"    and alpha-blockers) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. Regression of LVH continues gradually over time (three years or more) and may be associated with complete reversal of LVH and other abnormalities induced by hypertension such as left atrial enlargement and diastolic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, regression may be less pronounced with diuretics and beta blockers and is largely absent with direct vasodilators (such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"     hydralazine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"     minoxidil",
"    </a>",
"    ) and some calcium channel blockers, despite adequate BP control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/18\">",
"     18",
"    </a>",
"    ]. The ineffectiveness of direct vasodilators probably reflects the reflex stimulation of norepinephrine and angiotensin II release induced by these drugs, since these hormones may directly promote the development of LVH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=see_link&amp;anchor=H4#H4\">",
"     \"Definition and pathogenesis of left ventricular hypertrophy in hypertension\", section on 'Role of renin-angiotensin system'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A meta-analysis published in 2003 evaluated the relative efficacy of different antihypertensive drugs for their ability to reverse LVH in patients with hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/18\">",
"     18",
"    </a>",
"    ]. Eighty trials that included 146 and 17 active treatment and placebo arms, respectively, were evaluated. After statistical adjustments for length of therapy and degree of blood pressure lowering, the relative reductions in left ventricular mass index were (",
"    <a class=\"graphic graphic_figure graphicRef82558 \" href=\"UTD.htm?42/42/43693\">",
"     figure 4",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Angiotensin II receptor blockers (ARBs) &mdash; 13 percent",
"     </li>",
"     <li>",
"      Calcium channel blockers &mdash; 11 percent",
"     </li>",
"     <li>",
"      ACE inhibitors &mdash; 10 percent",
"     </li>",
"     <li>",
"      Diuretics &mdash; 8 percent",
"     </li>",
"     <li>",
"      Beta blockers &mdash; 6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    ARBs, calcium channel blockers, and ACE inhibitors produced significantly more regression than beta blockers. The clinical importance of this finding is uncertain since there is no evidence that more rapid regression of LVH is associated with improved long-term outcomes. The choice of antihypertensive therapy is usually based upon other factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"     \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of ARBs in the regression of LVH was evaluated in the LIFE trial, which compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    in hypertensive patients with ECG evidence of LVH [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. The degree of regression, using ECG criteria, was approximately twice as great at five years with losartan than with atenolol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further compare the efficacy of different agents, the PRESERVE trial randomly assigned 303 ethnically diverse, hypertensive patients with LVH at baseline to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    (10 to 20",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or long-acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/5/12377?source=see_link\">",
"     nifedipine",
"    </a>",
"    (30 to 60",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/26\">",
"     26",
"    </a>",
"    ]. There were no differences between the two groups in the reduction of blood pressure or LV mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cardiac function after regression of LVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression of LVH is associated with improved systolic performance, enhanced stroke volume, and no increase in the risk of decompensation if the blood pressure rises [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/27\">",
"     27",
"    </a>",
"    ]. Regression of LVH may also have other benefits, including a reduction in the number of ventricular premature beats, decreased vulnerability to inducible ventricular fibrillation, and a reduced incidence of atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/16,28\">",
"     16,28",
"    </a>",
"    ]. Whether these changes will diminish the risk of sudden death associated with LVH is not known. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=see_link\">",
"     \"Left ventricular hypertrophy and arrhythmia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The effect of LVH regression on diastolic dysfunction, one of the earliest changes in hypertension, has been less well studied. This issue was addressed in the LIFE trial, which randomly assigned 728 hypertensive patients with LVH by ECG criteria to antihypertensive therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/35/26168?source=see_link\">",
"     losartan",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/29\">",
"     29",
"    </a>",
"    ]. LVH regression was associated with significant improvement in left ventricular diastolic filling parameters after one year; there was no change in those without regression.",
"   </p>",
"   <p>",
"    Despite this improvement, evidence of diastolic dysfunction was still commonly observed, which may reflect the role of increased myocardial collagen content in diastolic dysfunction, an abnormality that may resolve more slowly than the increase in muscle mass. Consistent with this hypothesis is the observation that diastolic dysfunction continues to improve over time with long-term (three-year) follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Reduction in cardiovascular risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regression of LVH, either by ECG [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/17,30\">",
"     17,30",
"    </a>",
"    ] or echocardiography [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/31\">",
"     31",
"    </a>",
"    ] is associated with a reduction in cardiovascular risk. The magnitude of benefit was illustrated in a report from the Framingham Heart Study of 524 patients with LVH; during follow-up there were 269 new cardiovascular events [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/17\">",
"     17",
"    </a>",
"    ]. Changes in LVH on the ECG were measured as the sum of the R wave in aVL and the S wave in V3. Compared to patients with no serial change, those with a serial decline in voltage were at lower risk for cardiovascular disease (adjusted odds ratio 0.46 in men and 0.56 in women). In contrast, patients with a serial increase in voltage were at higher risk (adjusted odds ratio 1.86 in men and 1.61 in women).",
"   </p>",
"   <p>",
"    Similar benefits of LVH regression versus no regression were seen in an echocardiographic study of 387 patients with LVH (relative risk of first adverse cardiac events 0.36) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/31\">",
"     31",
"    </a>",
"    ]. The benefit was directly related to the degree of reduction in LV mass index, whether or not there was ECG evidence of LVH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ECHOCARDIOGRAPHY IN HYPERTENSIVE PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that LVH determined by echocardiography is an early sign of end-organ damage that correlates with increased cardiovascular risk raises the important question of when this procedure should be performed in hypertensive patients. This issue is complicated by the importance of the technical skill of the operator and the limitations of the technique in accurately measuring left ventricular mass itself or in detecting small changes with therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    .) The following are indications for echocardiography:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with mild diastolic hypertension (90 to 94 mmHg) who have no other cardiovascular risk factors or evidence of end-organ damage (including lack of or equivocal signs of LVH on the ECG). The demonstration of LVH by echocardiography is generally an indication for medical therapy, while nonpharmacologic modalities alone can be used if left ventricular mass is normal.",
"     </li>",
"     <li>",
"      In patients who have no evidence of end-organ damage who have either severe or refractory hypertension or hypertension that is present in the doctor's office but not at home or work. The absence of LVH in this setting suggests either hypertension of recent onset or white coat hypertension. The presence of the latter can be confirmed by ambulatory blood pressure monitoring. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=see_link\">",
"       \"Ambulatory blood pressure monitoring and white coat hypertension in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with known or suspected concomitant heart disease in whom the heart disease itself needs further evaluation or in whom the type of heart disease might suggest a particular form of antihypertensive therapy. As an example, an ACE inhibitor or ARB would be preferred in a patient with systolic dysfunction or mitral regurgitation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=see_link\">",
"       \"Overview of the therapy of heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who have a bundle branch block on ECG.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these indications, performance of an echocardiogram for the purpose of measuring LV mass is not recommended for the selection of antihypertensive therapy or for assessment of left ventricular mass in patients without adequate blood pressure control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Limited echocardiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important limitation to the use of echocardiography is its high cost. It has been suggested that, for the first two indications noted above, a less expensive procedure, limited to M-mode and 2-D echo for measurement of left ventricular wall thickness and mass, should be used [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17959/abstract/33,34\">",
"     33,34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5448634\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Left ventricular hypertrophy (LVH) is associated with increased incidence of heart failure, ventricular arrhythmias, death following myocardial infarction, decreased LV ejection fraction, sudden cardiac death, aortic root dilation, and a cerebrovascular event. The increase in cardiovascular risk is directly related to the degree of increase in left ventricular mass. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'LVH and increased cardiovascular risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Left ventricular hypertrophy can be diagnosed either by ECG or by echocardiography. Echocardiography is more sensitive and is the preferred test. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The increased cardiac risk associated with LVH is due in part to myocardial ischemia. The development of heart failure with LVH results from depressed left ventricular systolic function",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diastolic dysfunction. Electrical remodeling from LVH is associated with increased risk of atrial fibrillation, ventricular arrhythmias, especially torsades de pointes, and sudden death. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanisms for increased risk'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The regression of LVH is associated with a reduction in cardiovascular risk and improved cardiac function. The use of antihypertensive agents, weight loss, or dietary sodium restriction decreases cardiac mass in patients with LVH.(See",
"      <a class=\"local\" href=\"#H4\">",
"       'Effect of antihypertensive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regression of LVH is associated with use of angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), the direct renin inhibitor,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/59/9142?source=see_link\">",
"       aliskiren",
"      </a>",
"      , some calcium channel blockers (particularly",
"      <a class=\"drug drug_general\" href=\"UTD.htm?12/16/12554?source=see_link\">",
"       diltiazem",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/18/296?source=see_link\">",
"       amlodipine",
"      </a>",
"      ), and some sympatholytic agents (including",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"      and alpha-blockers). Regression of LVH is less with diuretics and beta blockers and is largely absent with direct vasodilators (such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/57/15254?source=see_link\">",
"       hydralazine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/5/32848?source=see_link\">",
"       minoxidil",
"      </a>",
"      ). However, the clinical importance of this finding is uncertain, and therefore the choice of antihypertensive agent is generally based on other factors. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Choice of drugs'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=see_link\">",
"       \"Choice of therapy in primary (essential) hypertension: Recommendations\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/1\">",
"      Elias MF, Sullivan LM, Elias PK, et al. Left ventricular mass, blood pressure, and lowered cognitive performance in the Framingham offspring. Hypertension 2007; 49:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/2\">",
"      Barrios V, Escobar C, Calderon A, et al. Prevalence of left ventricular hypertrophy detected by Cornell voltage-duration product in a hypertensive population. Blood Press 2008; 17:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/3\">",
"      Ang D, Lang C. The prognostic value of the ECG in hypertension: where are we now? J Hum Hypertens 2008; 22:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/4\">",
"      Levy, D, Garrison, RJ, Savage, DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study N Engl J Med 1990; 322:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/5\">",
"      Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/6\">",
"      Verdecchia P, Carini G, Circo A, et al. Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/7\">",
"      Haider AW, Larson MG, Benjamin EJ, Levy D. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 1998; 32:1454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/8\">",
"      Verdecchia P, Porcellati C, Reboldi G, et al. Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/9\">",
"      Drazner MH, Rame JE, Marino EK, et al. Increased left ventricular mass is a risk factor for the development of a depressed left ventricular ejection fraction within five years: the Cardiovascular Health Study. J Am Coll Cardiol 2004; 43:2207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/10\">",
"      Levy D, Garrison RJ, Savage DD, et al. Left ventricular mass and incidence of coronary heart disease in an elderly cohort. The Framingham Heart Study. Ann Intern Med 1989; 110:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/11\">",
"      Beache GM, Herzka DA, Boxerman JL, et al. Attenuated myocardial vasodilator response in patients with hypertensive hypertrophy revealed by oxygenation-dependent magnetic resonance imaging. Circulation 2001; 104:1214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/12\">",
"      Carluccio E, Tommasi S, Bentivoglio M, et al. Prognostic value of left ventricular hypertrophy and geometry in patients with a first, uncomplicated myocardial infarction. Int J Cardiol 2000; 74:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/13\">",
"      Burke AP, Farb A, Liang YH, et al. Effect of hypertension and cardiac hypertrophy on coronary artery morphology in sudden cardiac death. Circulation 1996; 94:3138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/14\">",
"      Norton GR, Woodiwiss AJ, Gaasch WH, et al. Heart failure in pressure overload hypertrophy. The relative roles of ventricular remodeling and myocardial dysfunction. J Am Coll Cardiol 2002; 39:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/15\">",
"      Gardin JM, McClelland R, Kitzman D, et al. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). Am J Cardiol 2001; 87:1051.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/16\">",
"      Okin PM, Wachtell K, Devereux RB, et al. Regression of electrocardiographic left ventricular hypertrophy and decreased incidence of new-onset atrial fibrillation in patients with hypertension. JAMA 2006; 296:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/17\">",
"      Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994; 90:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/18\">",
"      Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/19\">",
"      Ruggenenti P, Iliev I, Costa GM, et al. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT). Diabetes Care 2008; 31:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/20\">",
"      Ruilope LM, Schmieder RE. Left ventricular hypertrophy and clinical outcomes in hypertensive patients. Am J Hypertens 2008; 21:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/21\">",
"      Franz IW, T&ouml;nnesmann U, M&uuml;ller JF. Time course of complete normalization of left ventricular hypertrophy during long-term antihypertensive therapy with angiotensin converting enzyme inhibitors. Am J Hypertens 1998; 11:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/22\">",
"      Cuspidi C, Negri F, Zanchetti A. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention. Vasc Health Risk Manag 2008; 4:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/23\">",
"      Okin PM, Devereux RB, Gerdts E, et al. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Circulation 2006; 113:1588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/24\">",
"      Os I, Franco V, Kjeldsen SE, et al. Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension 2008; 51:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/25\">",
"      Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/26\">",
"      Devereux RB, Palmieri V, Sharpe N, et al. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial. Circulation 2001; 104:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/27\">",
"      Wachtell K, Palmieri V, Olsen MH, et al. Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study. Circulation 2002; 106:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/28\">",
"      Rials SJ, Wu Y, Xu X, et al. Regression of left ventricular hypertrophy with captopril restores normal ventricular action potential duration, dispersion of refractoriness, and vulnerability to inducible ventricular fibrillation. Circulation 1997; 96:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/29\">",
"      Wachtell K, Bella JN, Rokkedal J, et al. Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Circulation 2002; 105:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/30\">",
"      Okin PM, Devereux RB, Jern S, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 2004; 292:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/31\">",
"      Pierdomenico SD, Lapenna D, Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 2008; 21:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/32\">",
"      Ang DS, Fahey TP, Wright GA, Struthers AD. Development and validation of a clinical score to identify echocardiographic left ventricular hypertrophy in patients with cardiovascular disease. Am J Hypertens 2008; 21:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/33\">",
"      Sheps SG, Frohlich ED. Limited echocardiography for hypertensive left ventricular hypertrophy. Hypertension 1997; 29:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17959/abstract/34\">",
"      Verdecchia P, Sleight P, Mancia G, et al. Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. Circulation 2009; 120:1380.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3846 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-3CA5444EA1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17959=[""].join("\n");
var outline_f17_34_17959=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5448634\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LVH AND INCREASED CARDIOVASCULAR RISK",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanisms for increased risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFECT OF ANTIHYPERTENSIVE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Choice of drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cardiac function after regression of LVH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Reduction in cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      INDICATIONS FOR ECHOCARDIOGRAPHY IN HYPERTENSIVE PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Limited echocardiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5448634\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3846\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3846|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/36/25165\" title=\"figure 1\">",
"      LVH and cardiovascular risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/2/17449\" title=\"figure 2\">",
"      Cardiovascular event vs LV mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/35/19005\" title=\"figure 3\">",
"      LVH and sudden death",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/42/43693\" title=\"figure 4\">",
"      Regression of LV hypertrophy with antihypertensive therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7113?source=related_link\">",
"      Ambulatory blood pressure monitoring and white coat hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/25/19865?source=related_link\">",
"      Cardiac remodeling: Basic aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36314?source=related_link\">",
"      Choice of therapy in primary (essential) hypertension: Recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18247?source=related_link\">",
"      Definition and pathogenesis of left ventricular hypertrophy in hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/23/1401?source=related_link\">",
"      Left ventricular hypertrophy and arrhythmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/63/38906?source=related_link\">",
"      Overview of the therapy of heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15818?source=related_link\">",
"      Pathophysiology of diastolic heart failure",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_34_17960="Clinical features and pathogenesis of cancer cachexia";
var content_f17_34_17960=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical features and pathogenesis of cancer cachexia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Aminah Jatoi, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Charles L Loprinzi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17960/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/34/17960/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hippocrates described a syndrome of wasting and progressive inanition among patients who were ill and dying. The Greek words kakos, meaning \"bad things\", and hexus, meaning \"state of being\", have led to the term cachexia to describe this syndrome. Cachexia, a hypercatabolic state defined as accelerated loss of skeletal muscle in the context of a chronic inflammatory response, can occur in the setting of cancer as well as in chronic infection, AIDS, heart failure, rheumatoid arthritis and chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/1\">",
"     1",
"    </a>",
"    ]. Although body composition changes are not identical in all of these disease states, the term cachexia is used in all of these settings.",
"   </p>",
"   <p>",
"    Loss of appetite with weight loss is common among cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/2\">",
"     2",
"    </a>",
"    ]. One study evaluated 644 consecutive, mostly ambulatory cancer patients: decreased appetite, decreased food intake, and weight loss in excess of 5 percent of premorbid weight were present in more than one-half [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Furthermore, 54 percent were underweight when compared to their calculated ideal body weight.",
"   </p>",
"   <p>",
"    However, the profound weight loss suffered by patients with cachexia cannot be entirely attributed to poor caloric intake. Insufficient oral intake is superimposed upon complex metabolic aberrations that lead to an increase in basal energy expenditure and culminate in a loss of lean body mass from skeletal muscle wasting (sarcopenia) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast to simple starvation, which is characterized by a caloric deficiency that can be reversed with appropriate feeding, the weight loss of cachexia cannot be adequately treated with aggressive feeding [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Weight loss is the most obvious manifestation of cancer cachexia and is a marker for both progression of the syndrome and prognosis. In a multi-institutional, retrospective review of 3047 clinical protocol cancer patients from the Eastern Cooperative Oncology Group, weight loss of more than 5 percent of premorbid weight prior to the initiation of chemotherapy was predictive of early mortality. Weight loss was independent of disease stage, tumor histology, and patient performance status in its predictive value [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/7\">",
"     7",
"    </a>",
"    ]. There was also a trend towards lower response rates with the use of chemotherapy among weight-losing patients, but this trend reached statistical significance only among patients with breast cancer.",
"   </p>",
"   <p>",
"    In addition to poor prognosis and impaired response to therapy, cachexia may be a direct cause of death. A retrospective autopsy study found that approximately 1 percent of 486 patients with cancer died from no cause other than cachexia itself [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Here, we will review the clinical characteristics and pathogenesis of cancer cachexia. Potential pharmacologic therapies of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL CHARACTERISTICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer cachexia is characterized by diminished nutrient intake and progressive tissue depletion, both of which lead to weight loss. Changes in body composition, increasing debility, fluctuations in resting energy expenditure, loss of appetite, and at times, an inability to eat for mechanical reasons further characterize this syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Changes in body composition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A disproportionate and excessive loss of lean body mass is the hallmark of cancer cachexia. One study evaluated 50 patients with hematologic, pulmonary, gastrointestinal, and head and neck malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients were studied with tritiated water, prompt gamma neutron activation, and total body potassium measurement; these body composition measurements were compared to those of age- and sex-matched controls. Weight-losing patients with solid tumors suffered a loss of both fat and lean body mass. However, the loss of lean body mass, most notably skeletal muscle, was more dramatic. This response contrasts with that of simple starvation where, from a teleological standpoint, the host preserves lean body mass in an effort to survive [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alterations in resting energy expenditure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in resting energy expenditure (REE, also called basal metabolic rate) may contribute to the energy deficits that lead to wasting. An increase in REE, as measured by indirect calorimetry, has been observed in patients with lung cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], hematologic malignancies, and sarcomas [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/13,14\">",
"     13,14",
"    </a>",
"    ], and is thought to contribute to the weight loss observed in cancer cachexia. In one series of patients with lung cancer, 74 percent had an elevation in REE while 30 percent had a weight loss of 10 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast, simple calorie restriction alone leads to a decline in REE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/15\">",
"     15",
"    </a>",
"    ]. Such a decline has also been observed in patients with gastrointestinal malignancies, a finding that may reflect partial starvation in patients unable to eat for mechanical reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Reduced dietary intake or absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anorexia and poor oral intake contribute to the energy deficits observed in cancer cachexia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/18\">",
"     18",
"    </a>",
"    ]. In one of the studies noted above, caloric intake was significantly lower (300",
"    <span class=\"nowrap\">",
"     kcal/day)",
"    </span>",
"    in weight-losing cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/12\">",
"     12",
"    </a>",
"    ]. Chemotherapy-related alterations in taste and smell may contribute to this loss of appetite [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. One study suggests that weight-losing cancer patients appear to maintain the same relative food preferences but consume all foods in lesser amount [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, a number of nonspecific factors associated with cancer may contribute to decreased nutrient intake or absorption. These include chemotherapy and radiotherapy induced anorexia, nausea, and vomiting; limited food intake due to dysphagia or abdominal pain or abdominal distention; early satiety due to an enlarged spleen or liver, an abdominal mass, or abdominal distention (ascites); and malabsorption resulting from tumor invasion of the gastrointestinal tract or intestinal resection.",
"   </p>",
"   <p>",
"    Anorexia may also result from central and peripheral influences of proinflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/1\">",
"     1",
"    </a>",
"    ]. Centrally, inflammatory cytokines act at the level of the hypothalamic nuclei, which control feeding behavior.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Alterations in nutrient metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer cachexia is often associated with important changes in nutrient metabolism. Many patients have a constellation of findings consisting of hyperglycemia, hypertriglyceridemia, and an exaggerated insulin response to a glucose load [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/23\">",
"     23",
"    </a>",
"    ]. Hypertriglyceridemia occurs in combination with increases in very low density lipoprotein production and lipolysis and reduced activity of adipose tissue lipoprotein lipase.",
"   </p>",
"   <p>",
"    These changes may result from the interaction between increased cytokine release and insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. As an example, tumor necrosis factor-alpha, which is often increased in patients with cancer cachexia (see",
"    <a class=\"local\" href=\"#H8\">",
"     'Cytokines'",
"    </a>",
"    below), has been implicated in the insulin resistance associated with obesity and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/26-29\">",
"     26-29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Protein breakdown is increased in patients with cancer cachexia, leading to enhanced amino acid release from skeletal muscle despite the reduction in muscle mass and negative nitrogen balance. The plasma concentration of certain amino acids tends to be elevated, perhaps in part because of decreased skeletal muscle uptake due to insulin resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have focused on the mechanisms underlying the metabolic and body composition changes observed in cancer cachexia. They suggest a potentially important role for cytokine activation and for several tumor-derived and potentially cachexia-inducing substances, the target of which appears to be skeletal muscle gene products [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Cytokines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple cytokines have been implicated in cancer cachexia. Because of their ability to increase REE [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/31,32\">",
"     31,32",
"    </a>",
"    ] and induce anorexia, [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/33,34\">",
"     33,34",
"    </a>",
"    ], tumor necrosis factor-alpha (TNF-alpha), interleukin (IL)-1 beta, and IL-6 have been viewed as plausible mediators of cancer cachexia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/35\">",
"     35",
"    </a>",
"    ]. Initial studies provided conflicting data as to whether an increase in serum cytokines occurs in cancer cachexia; the majority of studies have detected elevations in peripheral blood mononuclear cell cytokine concentrations, especially TNF-alpha and IL-6, among weight-losing patients with cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/36-40\">",
"     36-40",
"    </a>",
"    ]. TNF-alpha has also been implicated in weight loss in other settings such as chronic obstructive pulmonary disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=see_link\">",
"     \"Nutritional support in advanced lung disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The possible role of cytokines in several different cancers has been demonstrated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 87 patients with non-small cell lung cancer found that 26 had lost more than 10 percent of their pre-illness weight [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/39\">",
"       39",
"      </a>",
"      ]. The patients with weight loss manifested a significantly greater systemic inflammatory response characterized by increased plasma concentrations of soluble TNF receptor 55, IL-6, the acute phase reactant C-reactive protein, as well as other adhesion molecules.",
"     </li>",
"     <li>",
"      In a study of blood samples from 164 patients with prostate cancer, elevated serum IL-6 levels were observed in 38 patients with relapsed metastatic disease, compared to those with newly diagnosed prostate cancer or disease in remission [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/41\">",
"       41",
"      </a>",
"      ]. Among the entire study population, high IL-6 levels were associated with lower serum albumin, total protein, serum hemoglobin, and body mass index, and also were associated with poor performance status. Among patients with relapsed disease, an elevated serum IL-6 level correlated with significantly shorter survivals.",
"     </li>",
"     <li>",
"      Similar observations were made in cachectic patients with pancreatic cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/40\">",
"       40",
"      </a>",
"      ]. Hypermetabolic patients with evidence of an acute phase response had higher concentrations of TNF-alpha and IL-6 in peripheral blood mononuclear cells than patients without an acute inflammatory response.",
"     </li>",
"     <li>",
"      Additional evidence in support of the hypothesis that TNF-alpha, IL-1 beta, and IL-6 serve as mediators in cancer cachexia come from animal studies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Administration of any of these cytokines to laboratory animals induces cachexia [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/42-44\">",
"       42-44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cachexia in tumor-bearing animals can be partially attenuated by the administration of anti-cytokine antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/45-47\">",
"       45-47",
"      </a>",
"      ]. Similarly, transgenic IL-6 mice develop muscle atrophy which can be reversed by anti-IL-6 receptor antibodies [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/48\">",
"       48",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In knockout mice lacking the gene for the TNF-alpha receptor type I protein, tumor implantation is not associated with the protein breakdown and muscle wasting seen in wild-type mice [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/49\">",
"       49",
"      </a>",
"      ]. In mice, TNF activates the transcription factor nuclear factor kappa B, which inhibits the expression of MyoD, a factor normally required for muscle function and repair [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/50\">",
"       50",
"      </a>",
"      ]. The wasting effect of these pro-inflammatory cytokines appears to be targeted against the myosin heavy chain of skeletal muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Whether these same mechanisms come into play in the tumor-bearing host is unknown.",
"   </p>",
"   <p>",
"    It should be noted that an etiologic role for TNF-alpha in CACS was not supported by the lack of benefit from treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , a TNF-alpha inhibitor, in a randomized trial from the North Central Cancer Treatment Group. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link&amp;anchor=H15#H15\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\", section on 'Targeting TNF'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Proteolysis-inducing factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cachexia in the murine MAC16 adenocarcinoma model appears to be mediated by a 24-kilodalton proteoglycan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/52\">",
"     52",
"    </a>",
"    ]. This substance has direct proteolytic activity as demonstrated by excess tyrosine release upon in vitro incubation with isolated gastrocnemius muscle; this effect was reversed by the administration of antibodies to the proteoglycan [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The so-called proteolysis-inducing factor has been identified in the urine of weight-losing patients with a variety of malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/52,54\">",
"     52,54",
"    </a>",
"    ]. Initially, it appeared to be highly specific for cancer cachexia. In one report, the proteolysis-inducing factor was not detectable in patients with weight loss from burns, trauma, or sepsis, or in cancer patients with stable weight [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although initial studies suggested that the proteolysis-inducing factor was homologous across species, cloning of the human cDNA has demonstrated cross-species differences in the protein sequence and subsequent glycosylation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/55\">",
"     55",
"    </a>",
"    ]. Tumor xenografts expressing this human proteolysis-inducing factor failed to induce cachexia in a murine xenograft model, which has raised questions about a causal relationship between the human proteolysis-inducing factor and the development of cancer cachexia. Furthermore, recent clinical data that included 262 cancer patients, 160 of whom had detectable proteolysis inducing factor in their urine, did not provide any clinical validation of this marker with respect weight loss or prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These observations raise the strong possibility that proteolysis inducing factor may not hold relevance in humans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lipolysis and lipid mobilizing factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although wasting of lean body mass is a major aspect of cancer cachexia, loss of fat mass also occurs. A tumor-produced lipid-mobilizing factor (LMF) may contribute to the wasting of fat tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/57\">",
"     57",
"    </a>",
"    ]. One study evaluated 50 patients: 24 with cancer, 10 with Alzheimer disease who had weight loss, nine with Alzheimer disease without weight loss, and seven healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/58\">",
"     58",
"    </a>",
"    ]. Using an assay for lipid mobilization that involves the incubation of human serum or urine with murine adipocytes and subsequent measurement of glycerol release from adipocytes, these investigators found that patients with cancer demonstrated significantly higher rates of lipid mobilization compared to other patient groups.",
"   </p>",
"   <p>",
"    This factor has been isolated and characterized [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/59\">",
"     59",
"    </a>",
"    ]. It appears to be a 43-kilodalton proteoglycan similar in its amino acid sequence to Zn-alpha-2-glycoprotein, a ubiquitous protein whose function is largely unknown. In an animal model, administration of LMF stimulated glycerol release led to weight loss and caused a 42 percent reduction in carcass adiposity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/60\">",
"     60",
"    </a>",
"    ]. In a series of 16 patients with cancer, only those with weight loss had detectable concentrations of LMF in their urine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/59\">",
"     59",
"    </a>",
"    ], a finding that suggests this factor may play a role in the human cancer cachexia syndrome.",
"   </p>",
"   <p>",
"    It is postulated that LMF acts to sensitize adipose tissue to lipolytic stimuli by increasing cyclic AMP production in adipocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/61\">",
"     61",
"    </a>",
"    ]. This effect may be mediated through the beta-adrenergic receptor, with increased receptor number or G protein expression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/57,61\">",
"     57,61",
"    </a>",
"    ]. The lipolytic effect appears to be attenuated by eicosapentaenoic acid (EPA) which appears to directly inhibit adenylate cyclase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/57,62\">",
"     57,62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although preclinical data suggested the possibility that other mechanisms of loss of fat tissue may be operative (eg, tumor-induced impairment in the formation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lipid storage capacity of adipose tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/63\">",
"     63",
"    </a>",
"    ]), increased fat cell lipolysis and not reduced lipogenesis or adipocyte cell death appears to be the primary cause of fat loss in this condition [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     The ATP-ubiquitin-proteasome pathway",
"    </span>",
"    &nbsp;&mdash;&nbsp;These multiple purported mediators of cancer cachexia raise the question of what is happening at the tissue level when wasting occurs. Activation of the ATP-ubiquitin-proteasome pathway may play an important role in cancer-associated tissue wasting as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rats bearing the Yoshida AH-130 ascites hepatoma manifest notable muscle wasting after tumor implantation, including a 30 percent loss of the gastrocnemius and extensor digitorum longus muscles. By day 7 after tumor implantation, free ubiquitin and ubiquitin conjugates were higher in the gastrocnemius muscle of tumor-implanted rats than in muscles from control rats [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/66,67\">",
"       66,67",
"      </a>",
"      ]. There was also an increase in ubiquitin mRNA levels in skeletal muscle of tumor-bearing animals when compared to pair-fed animals [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The proteolysis-inducing factor described above can activate the ATP-ubiquitin-dependent proteolytic pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/68\">",
"       68",
"      </a>",
"      ], although, as also mentioned above, more recent studies have raised questions about the role of proteolysis-inducing factor in cancer-associated weight loss [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/56,69\">",
"       56,69",
"      </a>",
"      ]. Similarly, the administration of TNF-alpha to rats increases free ubiquitin and ubiquitin conjugates in rat muscle [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/70\">",
"       70",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several proinflammatory cytokines, including TNF and IL-1, stimulate production of ubiquitin messenger RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, the ubiquitin-proteasome pathway may be the final common pathway mediating protein degradation in cachexia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/72\">",
"     72",
"    </a>",
"    ]. Although the specific muscle receptors that trigger activation of the ATP-ubiquitin-proteasome system have not been elucidated, future treatment strategies for this entity might directly target this pathway in wasting tissues. One preliminary study with the proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    did not result in reversal of the cancer",
"    <span class=\"nowrap\">",
"     anorexia/weight",
"    </span>",
"    loss syndrome in patients with pancreatic cancer, but further studies of this approach are needed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17960/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=see_link\">",
"     \"Pharmacologic management of cancer anorexia/cachexia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Cancer treatment and sarcopenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cancer treatment may also contribute to loss of lean body mass in patients with advanced cancer. Examples include the muscle wasting seen with androgen deprivation therapy in men with advanced prostate cancer, and a similar loss of skeletal muscle mass (sarcopenia) that has been reported in patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , a multitargeted tyrosine kinase inhibitor, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , a monoclonal antibody targeting the vascular endothelial growth factor (VEGF). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=see_link&amp;anchor=H20#H20\">",
"     \"Side effects of androgen deprivation therapy\", section on 'Changes in body composition and metabolism'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=see_link&amp;anchor=H1557944583#H1557944583\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\", section on 'Sorafenib and muscle wasting/sarcopenia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=see_link\">",
"       \"Patient information: Managing loss of appetite and weight loss with cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15049132\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cachexia, a hypercatabolic state defined as accelerated loss of skeletal muscle in the context of a chronic inflammatory response, can occur in the setting of cancer as well as in chronic infection, AIDS, heart failure, rheumatoid arthritis and chronic obstructive pulmonary disease. While loss of appetite with weight loss is common among cancer patients, the profound weight loss suffered by patients with cachexia cannot be entirely attributed to poor caloric intake. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A disproportionate and excessive loss of lean body mass is the hallmark of cancer cachexia. Alterations in resting energy expenditure (REE, also called basal metabolic rate) may contribute to the energy deficits that lead to wasting. Anorexia and poor oral intake contribute to the energy deficits observed in cancer cachexia, as do alterations in nutrient metabolism (eg, increased protein breakdown). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Clinical characteristics'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A number of studies focusing on the mechanisms underlying the metabolic and body composition changes observed in cancer cachexia suggest a potentially important role for cytokine activation and for several tumor-derived and potentially cachexia-inducing substances, the target of which appears to be skeletal muscle gene products. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In some cases, cancer treatment may also contribute to loss of lean body mass in patients with advanced cancer. Examples include the muscle wasting seen with androgen deprivation therapy in men with advanced prostate cancer, and a similar loss of skeletal muscle mass (sarcopenia) that has been reported with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , a multitargeted tyrosine kinase inhibitor used for the treatment of advanced renal cell and liver cancer. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Cancer treatment and sarcopenia'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/1\">",
"      Kotler DP. Cachexia. Ann Intern Med 2000; 133:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/2\">",
"      Teunissen SC, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: a systematic review. J Pain Symptom Manage 2007; 34:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/3\">",
"      Oncology. Clin Privil White Pap 2000; :1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/4\">",
"      Tchekmedyian NS. Costs and benefits of nutrition support in cancer. Oncology (Williston Park) 1995; 9:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/5\">",
"      Tisdale MJ. Cachexia in cancer patients. Nat Rev Cancer 2002; 2:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/6\">",
"      McGeer AJ, Detsky AS, O'Rourke K. Parenteral nutrition in cancer patients undergoing chemotherapy: a meta-analysis. Nutrition 1990; 6:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/7\">",
"      Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980; 69:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/8\">",
"      Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975; 6:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/9\">",
"      Cohn SH, Gartenhaus W, Sawitsky A, et al. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism 1981; 30:222.",
"     </a>",
"    </li>",
"    <li>",
"     Keys A, Brozek J, Henschel A, et al. The Biology of Human Starvation, University of Minnesota Press, St. Paul 1950.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/11\">",
"      Fredrix EW, Wouters EF, Soeters PB, et al. Resting energy expenditure in patients with non-small cell lung cancer. Cancer 1991; 68:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/12\">",
"      Staal-van den Brekel AJ, Schols AM, ten Velde GP, et al. Analysis of the energy balance in lung cancer patients. Cancer Res 1994; 54:6430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/13\">",
"      Stallings VA, Vaisman N, Chan HS, et al. Energy metabolism in children with newly diagnosed acute lymphoblastic leukemia. Pediatr Res 1989; 26:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/14\">",
"      Peacock JL, Inculet RI, Corsey R, et al. Resting energy expenditure and body cell mass alterations in noncachectic patients with sarcomas. Surgery 1987; 102:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/15\">",
"      Leibel RL, Rosenbaum M, Hirsch J. Changes in energy expenditure resulting from altered body weight. N Engl J Med 1995; 332:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/16\">",
"      Dempsey DT, Feurer ID, Knox LS, et al. Energy expenditure in malnourished gastrointestinal cancer patients. Cancer 1984; 53:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/17\">",
"      Dempsey DT, Knox LS, Mullen JL, et al. Energy expenditure in malnourished patients with colorectal cancer. Arch Surg 1986; 121:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/18\">",
"      Theologides A, Ehlert J, Kennedy BJ. The calorie intake of patients with advanced cancer. Minn Med 1976; 59:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/19\">",
"      Steinbach S, Hummel T, B&ouml;hner C, et al. Qualitative and quantitative assessment of taste and smell changes in patients undergoing chemotherapy for breast cancer or gynecologic malignancies. J Clin Oncol 2009; 27:1899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/20\">",
"      Bernhardson BM, Tishelman C, Rutqvist LE. Self-reported taste and smell changes during cancer chemotherapy. Support Care Cancer 2008; 16:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/21\">",
"      Temmel AF, Quint C, Schickinger-Fischer B, et al. Characteristics of olfactory disorders in relation to major causes of olfactory loss. Arch Otolaryngol Head Neck Surg 2002; 128:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/22\">",
"      Levine JA, Morgan MY. Preservation of macronutrient preferences in cancer anorexia. Br J Cancer 1998; 78:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/23\">",
"      Rofe AM, Bourgeois CS, Coyle P, et al. Altered insulin response to glucose in weight-losing cancer patients. Anticancer Res 1994; 14:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/24\">",
"      Tracey KJ, Cerami A. Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. Am J Trop Med Hyg 1992; 47:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/25\">",
"      Hardard&oacute;ttir I, Gr&uuml;nfeld C, Feingold KR. Effects of endotoxin and cytokines on lipid metabolism. Curr Opin Lipidol 1994; 5:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/26\">",
"      Hofmann C, Lorenz K, Braithwaite SS, et al. Altered gene expression for tumor necrosis factor-alpha and its receptors during drug and dietary modulation of insulin resistance. Endocrinology 1994; 134:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/27\">",
"      Peraldi P, Xu M, Spiegelman BM. Thiazolidinediones block tumor necrosis factor-alpha-induced inhibition of insulin signaling. J Clin Invest 1997; 100:1863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/28\">",
"      Hotamisligil GS, Johnson RS, Distel RJ, et al. Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein. Science 1996; 274:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/29\">",
"      Zinman B, Hanley AJ, Harris SB, et al. Circulating tumor necrosis factor-alpha concentrations in a native Canadian population with high rates of type 2 diabetes mellitus. J Clin Endocrinol Metab 1999; 84:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/30\">",
"      Pisters PW, Pearlstone DB. Protein and amino acid metabolism in cancer cachexia: investigative techniques and therapeutic interventions. Crit Rev Clin Lab Sci 1993; 30:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/31\">",
"      Tocco-Bradley R, Georgieff M, Jones CT, et al. Changes in energy expenditure and fat metabolism in rats infused with interleukin-1. Eur J Clin Invest 1987; 17:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/32\">",
"      Van der Poll T, Romijn JA, Endert E, et al. Tumor necrosis factor mimics the metabolic response to acute infection in healthy humans. Am J Physiol 1991; 261:E457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/33\">",
"      Hellerstein MK, Meydani SN, Meydani M, et al. Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 1989; 84:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/34\">",
"      Sonti G, Ilyin SE, Plata-Salam&aacute;n CR. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996; 270:R1394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/35\">",
"      Davis MP, Dreicer R, Walsh D, et al. Appetite and cancer-associated anorexia: a review. J Clin Oncol 2004; 22:1510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/36\">",
"      Walsh D, Mahmoud F, Barna B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer 2003; 11:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/37\">",
"      Zeisler H, Tempfer C, Joura EA, et al. Serum interleukin 1 in ovarian cancer patients. Eur J Cancer 1998; 34:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/38\">",
"      Mantovani G, Macci&ograve; A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med (Berl) 2000; 78:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/39\">",
"      Staal-van den Brekel AJ, Dentener MA, Schols AM, et al. Increased resting energy expenditure and weight loss are related to a systemic inflammatory response in lung cancer patients. J Clin Oncol 1995; 13:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/40\">",
"      Falconer JS, Fearon KC, Plester CE, et al. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/41\">",
"      Kuroda K, Nakashima J, Kanao K, et al. Interleukin 6 is associated with cachexia in patients with prostate cancer. Urology 2007; 69:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/42\">",
"      Ling PR, Schwartz JH, Bistrian BR. Mechanisms of host wasting induced by administration of cytokines in rats. Am J Physiol 1997; 272:E333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/43\">",
"      Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol 1989; 256:R659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/44\">",
"      Greenberg AS, Nordan RP, McIntosh J, et al. Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia. Cancer Res 1992; 52:4113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/45\">",
"      Gelin J, Moldawer LL, L&ouml;nnroth C, et al. Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991; 51:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/46\">",
"      Strassmann G, Masui Y, Chizzonite R, Fong M. Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor. J Immunol 1993; 150:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/47\">",
"      Strassmann G, Fong M, Kenney JS, Jacob CO. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992; 89:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/48\">",
"      Tsujinaka T, Fujita J, Ebisui C, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/49\">",
"      Llovera M, Garc&iacute;a-Mart&iacute;nez C, L&oacute;pez-Soriano J, et al. Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol 1998; 142:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/50\">",
"      Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000; 289:2363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/51\">",
"      Acharyya S, Ladner KJ, Nelsen LL, et al. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest 2004; 114:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/52\">",
"      Todorov P, Cariuk P, McDevitt T, et al. Characterization of a cancer cachectic factor. Nature 1996; 379:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/53\">",
"      Todorov PT, McDevitt TM, Cariuk P, et al. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996; 56:1256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/54\">",
"      Cabal-Manzano R, Bhargava P, Torres-Duarte A, et al. Proteolysis-inducing factor is expressed in tumours of patients with gastrointestinal cancers and correlates with weight loss. Br J Cancer 2001; 84:1599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/55\">",
"      Monitto CL, Dong SM, Jen J, Sidransky D. Characterization of a human homologue of proteolysis-inducing factor and its role in cancer cachexia. Clin Cancer Res 2004; 10:5862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/56\">",
"      Wieland BM, Stewart GD, Skipworth RJ, et al. Is there a human homologue to the murine proteolysis-inducing factor? Clin Cancer Res 2007; 13:4984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/57\">",
"      Khan S, Tisdale MJ. Catabolism of adipose tissue by a tumour-produced lipid-mobilising factor. Int J Cancer 1999; 80:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/58\">",
"      Groundwater P, Beck SA, Barton C, et al. Alteration of serum and urinary lipolytic activity with weight loss in cachectic cancer patients. Br J Cancer 1990; 62:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/59\">",
"      Todorov PT, McDevitt TM, Meyer DJ, et al. Purification and characterization of a tumor lipid-mobilizing factor. Cancer Res 1998; 58:2353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/60\">",
"      Hirai K, Hussey HJ, Barber MD, et al. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998; 58:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/61\">",
"      Islam-Ali B, Khan S, Price SA, Tisdale MJ. Modulation of adipocyte G-protein expression in cancer cachexia by a lipid-mobilizing factor (LMF). Br J Cancer 2001; 85:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/62\">",
"      Price SA, Tisdale MJ. Mechanism of inhibition of a tumor lipid-mobilizing factor by eicosapentaenoic acid. Cancer Res 1998; 58:4827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/63\">",
"      Bing C, Russell S, Becket E, et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer 2006; 95:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/64\">",
"      Ryd&eacute;n M, Agustsson T, Laurencikiene J, et al. Lipolysis--not inflammation, cell death, or lipogenesis--is involved in adipose tissue loss in cancer cachexia. Cancer 2008; 113:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/65\">",
"      Das SK, Eder S, Schauer S, et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011; 333:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/66\">",
"      Llovera M, Garcia-Martinez C, Agell N, et al. Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer 1995; 61:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/67\">",
"      Baracos VE, DeVivo C, Hoyle DH, Goldberg AL. Activation of the ATP-ubiquitin-proteasome pathway in skeletal muscle of cachectic rats bearing a hepatoma. Am J Physiol 1995; 268:E996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/68\">",
"      Lorite MJ, Smith HJ, Arnold JA, et al. Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer 2001; 85:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/69\">",
"      Jatoi A, Foster N, Wieland B, et al. The proteolysis-inducing factor: in search of its clinical relevance in patients with metastatic gastric/esophageal cancer. Dis Esophagus 2006; 19:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/70\">",
"      Garc&iacute;a-Mart&iacute;nez C, Llovera M, Agell N, et al. Ubiquitin gene expression in skeletal muscle is increased during sepsis: involvement of TNF-alpha but not IL-1. Biochem Biophys Res Commun 1995; 217:839.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/71\">",
"      Llovera M, Garc&iacute;a-Mart&iacute;nez C, Agell N, et al. TNF can directly induce the expression of ubiquitin-dependent proteolytic system in rat soleus muscles. Biochem Biophys Res Commun 1997; 230:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/72\">",
"      Mitch WE, Goldberg AL. Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med 1996; 335:1897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17960/abstract/73\">",
"      Jatoi A, Alberts SR, Foster N, et al. Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group. Support Care Cancer 2005; 13:381.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2817 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-8189A37D88-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17960=[""].join("\n");
var outline_f17_34_17960=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15049132\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL CHARACTERISTICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Changes in body composition",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alterations in resting energy expenditure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Reduced dietary intake or absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Alterations in nutrient metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Cytokines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Proteolysis-inducing factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lipolysis and lipid mobilizing factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      The ATP-ubiquitin-proteasome pathway",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Cancer treatment and sarcopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15049132\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/39/43639?source=related_link\">",
"      Nutritional support in advanced lung disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/40/1667?source=related_link\">",
"      Patient information: Managing loss of appetite and weight loss with cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/63/5113?source=related_link\">",
"      Pharmacologic management of cancer anorexia/cachexia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21993?source=related_link\">",
"      Side effects of androgen deprivation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_34_17961="Myelofibrosis bone marrow";
var content_f17_34_17961=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57384&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Myelofibrosis bone marrow biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow biopsy in myelofibrosis shows replacement of the marrow with fibrous tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal bone marrow biopsy at low power",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Low power view of a normal bone marrow biopsy. The overall cellularity is between 30 and 70 percent, with the remainder of the space being occupied by fat and stroma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stanley L Schrier, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17961=[""].join("\n");
var outline_f17_34_17961=null;
var title_f17_34_17962="Investigational therapies in the medical management of Crohn's disease";
var content_f17_34_17962=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Investigational therapies in the medical management of Crohn's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Joshua R Korzenik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/34/17962/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/34/17962/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4393207\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease (CD) is the focus of unprecedented interest for new potential therapeutics. Since the approval of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for the treatment of Crohn's disease in 1998, CD has been viewed as an excellent proving ground for antiinflammatory biologics.",
"   </p>",
"   <p>",
"    Despite increasing available therapies, the approved therapies have limited efficacy, and there continues to be concern related to their safety. Thus, a large unmet need exists for the treatment of CD.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     Mesalamine",
"    </a>",
"    , though used widely in Crohn's disease, has a minor role with little data supportive of a significant benefit, if any, for the treatment of CD. Glucocorticoids, while clinically useful, do not completely control the disease in many patients and have no role for maintenance. While some patients respond to the available anti-TNF agent, many fail to respond or lose response over time. Thus, newer approaches are being evaluated.",
"   </p>",
"   <p>",
"    The dramatic advances in mucosal immunology have revealed a broad set of new targets to resolve the inflammation and symptoms of the disease. The prevailing understanding of CD suggests that the intestinal inflammation is initiated by an aberrant innate immune response, which eventuates in a T-cell driven process, characterized by a T-helper cell 1 type cytokine profile. Many new treatments focus on inhibiting, suppressing, or altering T cell differentiation. With the identification of a T cell subset, Th17, which may be responsible for much of the inflammatory process and production of inflammatory cytokines, a new set of therapeutic antibodies are in early phase of testing. The importance of Treg (a T cell subset that regulates other T cells) has also opened other potential avenues for influencing activated T cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=see_link&amp;anchor=H1232221#H1232221\">",
"     \"Normal B and T lymphocyte development\", section on 'Th17 cells'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to efforts to manipulate T cells, T cell products, or inflammatory pathways, other therapeutics are being investigated that take very different theoretical approaches. Examples include the administration or cytokines to stimulate innate immunity, the use of helminths to restore T cell regulation, or the use of prebiotics, complex carbohydrates to alter the gut flora.",
"   </p>",
"   <p>",
"    This topic review will discuss experimental treatments for Crohn's disease. None of the treatments that will be discussed is currently approved for routine clinical application. Furthermore, because many of these agents are in early stages of development, information regarding their efficacy and safety is derived largely from unpublished sources of data.",
"   </p>",
"   <p>",
"    Conventional treatments for Crohn's disease (such as 6-mercaptopurine,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ) and an overview of the medical management of Crohn's disease are discussed in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393214\">",
"    <span class=\"h1\">",
"     PROINFLAMMATORY CYTOKINE INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potential targets for the treatment of Crohn's disease (CD) have proliferated tremendously in recent years. The intestinal mucosa persists in a state of controlled inflammation where proinflammatory cytokines (such as tumor necrosis factor [TNF]-alpha, IL-1, IL-6, IL-8, and IL-12) are counterbalanced by antiinflammatory cytokines (such as IL-4, IL-10, IL-11, and IL-13). Because IBD represents a state of dysregulated inflammation, drugs that can augment the antiinflammatory response have the potential to downregulate inflammation and thereby improve the disease. While the demarcation of Th1 and Th2 types of disease in humans is less clear than in murine models, Crohn's disease continues to be viewed as a Th1 disease, with interferon and IL-12 as dominant cytokines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Anti-TNF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    , a monoclonal antibody with high specificity for and affinity to tumor necrosis factor (TNF)-alpha, is highly effective in the treatment of patients with moderately to severely active Crohn's disease and patients with fistulizing Crohn's disease, who have had an inadequate response to conventional therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     Adalimumab",
"    </a>",
"    and certolizumab have been approved by the US Food and Drug Administration for use in Crohn's disease. Other anti-TNF agents have been investigated. Except for issues of antigenicity, which will vary with each agent, these anti-TNF drugs will likely all share similar safety concerns as have been seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , including the risk of infection, reactivation of tuberculosis, and lymphoma, among other adverse events.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     CDP571",
"    </span>",
"    &nbsp;&mdash;&nbsp;CDP571 (Humicade) is a humanized, IgG4 monoclonal anti-TNF-alpha antibody [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/1\">",
"     1",
"    </a>",
"    ]. Initial studies have shown mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. This compound is not currently in active trials and further development is unlikely.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Etanercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    (Enbrel&reg;) is an injectable TNF p75 receptor fusion protein that binds to and inactivates human TNF. It is currently used to treat rheumatoid arthritis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a pilot study, the drug was associated with a reduction in disease activity in 6 of 10 patients with active Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/5\">",
"     5",
"    </a>",
"    ]. However, no benefit was observed in a subsequent placebo-controlled four-week trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Onercept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Onercept is a recombinant form of the natural human soluble p55 TNF receptor. A clinical benefit was suggested in a pilot study involving 12 patients with active Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/7\">",
"     7",
"    </a>",
"    ]. However, a subsequent placebo-controlled trial found no significant benefit for clinical response or induction of remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9385263\">",
"    <span class=\"h3\">",
"     Other anti-TNF agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additional anti-TNF agents are anticipated to be more widely investigated in the near future.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/24/35206?source=see_link\">",
"     Golimumab",
"    </a>",
"    , currently approved for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, is being studied in ulcerative colitis, but is anticipated to be studied in Crohn&rsquo;s disease as well. A different approach, TNF kinoids, induces production of polyclonal antibodies against multiple epitopes of TNF-alpha as a means of overcoming antibody mediated resistance seen with other anti-TNF antibodies. A pilot study in patients with Crohn&rsquo;s disease reported by the manufacturer suggested a benefit and further studies are planned [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other immunosuppressive agents that in part target TNF are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9385270\">",
"    <span class=\"h2\">",
"     Semapimod",
"    </span>",
"    &nbsp;&mdash;&nbsp;Semapimod, an intravenously administered JNK and p38 MAP kinase inhibitor had a promising open label trial [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/10\">",
"     10",
"    </a>",
"    ]. However, a further trial failed to demonstrate a benefit, although the study was discontinued before the target enrollment was achieved [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393221\">",
"    <span class=\"h2\">",
"     Thalidomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     Thalidomide",
"    </a>",
"    decreases production of proinflammatory cytokines including TNF-alpha and IL-12. It was banned after its use in pregnancy for hyperemesis was found to cause severe birth defects. However, the antiinflammatory effects of thalidomide have generated renewed interest in its use in a variety of conditions.",
"   </p>",
"   <p>",
"    Its safety and efficacy in Crohn's disease were evaluated in two open label pilot trials [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. The first enrolled 12 adult patients with Crohn's disease that was refractory to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or who were intolerant of 6-mercaptopurine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (50 or 100 mg) for 12 weeks. At the end of treatment, a clinical response was observed in 70 percent of patients, with clinical remission in 20 percent. Steroids could be discontinued in 44 percent of patients. Toxicity included drowsiness, peripheral neuropathy, edema, and dermatitis.",
"   </p>",
"   <p>",
"    In the second study, 22 patients with refractory Crohn's disease were treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    (200 or 300 mg orally QHS) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/13\">",
"     13",
"    </a>",
"    ]. Fourteen patients completed 12 weeks of treatment, all of whom achieved a clinical response, including nine who achieved clinical remission. Five of six patients with fistulas had complete closure of all fistulas after 12 weeks of therapy. Six patients withdrew from the study within the first four weeks (two requiring surgery for refractory or worsening symptoms, and four others because of side effects or lack of perceived improvement).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     Lenalidomide",
"    </a>",
"    is a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    analogue that has been suggested to be a more potent inhibitor of TNF and other inflammatory cytokines than thalidomide. In addition, it does not produce some of the significant side effects of thalidomide, such as neuropathy and drowsiness. It was studied in a randomized controlled trial that assigned 89 subjects with active Crohn's disease to one of two doses of lenalidomide or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/14\">",
"     14",
"    </a>",
"    ]. This 12-week study failed to demonstrate any efficacy in Crohn's disease. Whether biologic effects between these two compounds differ or whether this questions the results of the open label studies of thalidomide for Crohn's disease remains uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Anti-interleukin 12 and 23 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-12 has a central role in driving the inflammatory response mediated by type 1 helper cells. A placebo-controlled trial evaluated the efficacy of an antibody against IL-12 (briakinumab, formerly known as",
"    <span class=\"nowrap\">",
"     ABT-874/J695)",
"    </span>",
"    in 79 patients with active Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/16\">",
"     16",
"    </a>",
"    ]. Patients were randomly assigned to a seven-week course of subcutaneous injections (1 or 3 mg per kg) or placebo. Seven weeks of uninterrupted treatment with the 3 mg dose was associated with a significantly higher rate of response than placebo (75 versus 25 percent). However, the differences were no longer significant at 18 weeks of follow-up. Adverse events were similar to placebo except for a higher rate of local reactions at the injection site in the active intervention arms. A larger phase IIb randomized controlled trial of 230 patients failed to identify a benefit for induction of remission at week six (the primary endpoint), though a modest benefit was seen at week 12, particularly benefiting those previously treated with anti-TNF agents [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IL-12 shares a common subunit, p40, with IL-23, a cytokine important in the activation of a T cell subset. While IL-12 is important in Th1 differentiation, IL-23 is central for the development of Th17 cells. Antibodies directed against IL-12 also bind to this shared subunit of IL-23, consequently inhibiting two important targets in T cell differentiation. An oral inhibitor of these targets, apilimod mesylate (STA 5326), has also been studied in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another antibody directed against this shared subunit (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/46/742?source=see_link\">",
"     ustekinumab",
"    </a>",
"    ) was more effective than placebo in inducing a clinical response especially in patients with moderate to severe Crohn&rsquo;s disease previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/19\">",
"     19",
"    </a>",
"    ]. In a phase 2 study, ustekinumab was also more effective than placebo in both the induction of a response and maintenance in adults with moderately to severely active CD refractory to tumor necrosis factor (TNF)-antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H2897067#H2897067\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Ustekinumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anti-interferon gamma antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon gamma is an important cytokine involved in cell-mediated immunity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link\">",
"     \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"    </a>",
"    .) A study evaluated the efficacy and safety of fontolizumab (HuZAF&trade;), a humanized anti-interferon gamma antibody in 133 patients with moderate or severe Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/21\">",
"     21",
"    </a>",
"    ]. Clinical improvement was observed in groups receiving 4 or 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    compared with placebo. Approximately one-half of patients in both groups were in remission by day 45 compared with only 14 percent of those receiving placebo, with a post-hoc analysis suggesting response most significantly among those with a C-reactive protein (CRP) &gt;10. The drug appeared to be well tolerated. However, a subsequent trial failed to demonstrate significant clinical effect [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Anti-interleukin 6 receptor monoclonal antibody (tocilizumab)",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, IL-6 is a proinflammatory cytokine. Thus, blockage of IL-6 activity has the potential to downregulate inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. A humanized monoclonal antibody directed against the IL-6 receptor (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , atlizumab, MRA) is in early clinical trials. An initial pilot study in patients with active Crohn's disease showed promising results with 80 percent (8 out of 10) responding at the full dose compared with 31 percent (4 out of 13) in the placebo group, although only two patients achieved remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/25\">",
"     25",
"    </a>",
"    ]. This compound has been approved by the FDA for rheumatoid arthritis and further development in Crohn's disease is anticipated in the near future.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Anti-interleukin 17 antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin 17 is a critical inducer of a CD4+ subset of T cells, TH17 cells. This T cell subset is proposed as central to the inflammatory response characteristic of Crohn's disease. A double-blind, placebo-controlled trial demonstrated that inhibition of IL-17A by secukinumab in Crohn's disease was ineffective, with lower response and remission rates and higher infection rates in the treated arm than in the placebo arm [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/26\">",
"     26",
"    </a>",
"    ]. Another study of the efficacy of an anti-IL-17 R in Crohn's disease was prematurely halted because of lack of efficacy. These data question the role of IL-17 in the pathogenesis of inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27729305\">",
"    <span class=\"h2\">",
"     Human recombinant immune-regulatory cytokines",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Interleukin-10",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin (IL)-10 is a cytokine that has antiinflammatory and immunosuppressant properties. Endogenous expression of IL-10 is increased in inflamed mucosa from patients with inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of recombinant IL-10 in Crohn's disease was first suggested in a pilot study in which 46 patients with active, steroid-resistant Crohn's disease were randomized to varying doses of IL-10 or placebo administered once daily intravenously for seven consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/28\">",
"     28",
"    </a>",
"    ]. Following treatment, the average score on the Crohn's disease activity index was lower among patients receiving active treatment (179 versus 226), although the results were not statistically significant.",
"   </p>",
"   <p>",
"    However, a meta-analysis that included three randomized trials with a total of 470 patients found no significant difference in complete or clinical remission rates between patients who received IL-10 and those who received placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two of the trials included in the meta-analysis showed the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, controlled dose finding study included 329 patients with active Crohn's disease refractory to conventional treatment who were randomized to IL-10 (varying doses given subcutaneously) or placebo for 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/30\">",
"       30",
"      </a>",
"      ]. No significant differences in the induction of remission were observed between the groups. However, clinical improvement was observed more often in the group receiving 8",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      of IL-10 compared with placebo (46 versus 27 percent). Treatment was well tolerated; a dose-dependent and fully reversible decrease in hemoglobin and platelet counts was observed.",
"     </li>",
"     <li>",
"      In another trial, 95 patients with active Crohn's disease who were not taking steroids or ASA drugs were randomized to varying doses of IL-10 or placebo for 28 days [",
"      <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/31\">",
"       31",
"      </a>",
"      ]. Remission was defined as a score on the Crohn's disease activity index of less than 150, with a decrease in baseline of at least 100 points, plus improvement or resolution on endoscopic appearance. Significantly more patients randomized to the 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day dose (but not the other doses) achieved remission at the end of the study (24 versus 0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A strain of recombinant bacteria that secretes IL-10 and is capable of colonizing the intestinal tract has been developed. The bacteria suppressed colitis in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/32\">",
"     32",
"    </a>",
"    ]. This approach presents an intriguing new method to deliver therapy directly to the intestinal mucosa and adds to the experience with other \"probiotic\" therapies. A pilot study in humans suggested a potential clinical benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/33\">",
"     33",
"    </a>",
"    ]. A phase IIa study with AG011 in ulcerative colitis showed no significant improvement of inflammation compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Interleukin-11",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interleukin-11 is a cytokine of mesenchymal cell origin that has a potent thrombocytopoietic effect and also had an unanticipated benefit on colitis in experimental animal models, providing a rationale for its use in IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. A dose ranging study involving 76 humans with active Crohn's disease suggested that short-term treatment (three weeks) significantly improved clinical response compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/37\">",
"     37",
"    </a>",
"    ]. A subsequent preliminary report from the same authors that included 148 patients with active Crohn's disease found that treated patients were significantly more likely to be in remission by six weeks compared with placebo (37 versus 16 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/38\">",
"     38",
"    </a>",
"    ]. By contrast, interleukin-11 was inferior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    in achieving induction of remission in a randomized controlled trial involving 51 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18726171\">",
"    <span class=\"h1\">",
"     INHIBITORS OF T CELLS OR T CELL DIFFERENTIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous compounds in development for Crohn's disease target T cell differentiation or activity as the culprit responsible for much of the tissue injury. An initial approach was to block T cells broadly with antibodies directed at CD3 or CD4 cell surface markers. Visilizumab, a humanized monoclonal antibody directed at CD3, a cell surface marker of activated T cells, has been studied in Crohn's disease. In an open label trial, 18 patients with active Crohn's disease received two doses of 10",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    which resulted in remission at day 59 in six patients (33 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, in two trials, a high percentage of individuals with Crohn's disease had cytokine release syndrome as well as an elevation of liver enzymes after administration of the compound [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/42\">",
"     42",
"    </a>",
"    ]. Visilizumab was not found to be efficacious for avoiding colectomy in severe steroid-refractory ulcerative colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CTLA-4 selective co-stimulation with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    has been approved for treatment of rheumatoid arthritis. CTLA-Ig inhibits the full activation of T cells by blocking effective co-stimulation. In four randomized controlled trials, abatacept was not found to be efficacious for induction of remission or maintenance of remission in patients with moderate to severe Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393242\">",
"    <span class=\"h1\">",
"     LEUKOCYTE ADHESION INHIBITORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adhesion molecules are involved in leukocyte migration and recruitment to sites of inflammation. Blockage of leukocyte migration has been proposed as a means of down regulating inflammation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Antisense oligonucleotides",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antisense oligonucleotides are nucleic acid sequences that bind to RNA or DNA with a high degree of specificity, and can thereby block expression of a specific protein [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/45\">",
"     45",
"    </a>",
"    ]. Antisense therapy is under investigation for a number of diseases including inflammatory bowel disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Intercellular adhesion molecule-1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intercellular adhesion molecule-1 (ICAM-1) is a transmembrane glycoprotein that has multiple functions involving propagation of inflammatory processes, and is upregulated in inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/46\">",
"     46",
"    </a>",
"    ]. Initial results in human pilot studies using antisense therapy against ICAM-1 were equivocal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Results of two subsequent placebo-controlled trials were negative [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393249\">",
"    <span class=\"h2\">",
"     Anti-integrin antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha-4 integrins are involved in leukocyte migration across vascular endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/50\">",
"     50",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1271?source=see_link\">",
"     Natalizumab",
"    </a>",
"    targets the alpha-4 subunit, which is present as a component of two distinct integrins, alpha-4-beta-1 and alpha-4-beta-7. These integrins each contribute to inflammatory bowel disease. Controlled trials have demonstrated the therapeutic benefit to this agent in patients with moderate to severe active Crohn's disease and the drug is on the market in the United States. Its widespread use is hampered by the risk of progressive multifocal leukoencephalopathy (PML). More gut-selective anti-adhesion molecule therapies are under development, including strategies inhibiting alpha-4-beta-7, beta-7, and Madcam-1.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393256\">",
"    <span class=\"h3\">",
"     Vedolizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vedolizumab is a recombinant humanized, anti alpha-4-beta-7 integrin monoclonal antibody, an integrin relatively specific to the gastrointestinal tract. &nbsp;A phase II study of Crohn's disease was suggestive of a dose-dependent benefit on clinical remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/51\">",
"     51",
"    </a>",
"    ]. Preliminary results of a large phase III trial (GEMINI) have demonstrated efficacy for vedolizumab in both ulcerative colitis and Crohn&rsquo;s disease and it is anticipated to be approved by the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. In a randomized trial, 1115 patients with moderately to severely active Crohn&rsquo;s disease who had failed at least one conventional therapy, including TNF-alpha antagonists, were randomized to vedolizumab (300 mg IV every four weeks or eight weeks) or placebo for one year, following six weeks of induction therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/54\">",
"     54",
"    </a>",
"    ]. In this trial, rates of clinical remission were significantly higher in patients treated with vedolizumab as compared with placebo (37 and 39 weeks versus 22 weeks).",
"   </p>",
"   <p>",
"    CCR9 inhibitor",
"    <span class=\"nowrap\">",
"     (CCX282-b/Traficet-EN)",
"    </span>",
"    appears promising in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/55\">",
"     55",
"    </a>",
"    ]. CCR9 is a highly specific receptor expressed predominately by T cells. When CCR9 or its chemokine ligand CCL25 (previously known as TECK) is overexpressed, it leads to the migration of T cells to the small and large intestines, which contributes to persistent inflammation. Inhibition of CCR9 with Traficet-EN decreases the migration of this subset of T cells. Results of a phase IIb placebo-controlled trial of this oral agent in Crohn&rsquo;s disease suggested a benefit in the induction phase, at the end of week 12, and at the completion of a 36-week maintenance phase [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/56\">",
"     56",
"    </a>",
"    ]. The PROTECT-1 trial had 436 individuals enrolled in the induction phase and randomized 241 responders to the maintenance phase with 47 percent maintaining remission compared with 31 percent in the placebo group (p = 0.01). A phase III trial will be initiated shortly.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393270\">",
"    <span class=\"h1\">",
"     OTHER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous",
"    <strong>",
"    </strong>",
"    other therapeutics are being investigated that take very different theoretical approaches:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727218\">",
"    <span class=\"h2\">",
"     Teduglutide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/33/10772?source=see_link\">",
"     Teduglutide",
"    </a>",
"    , an analog of glucagon-like peptide-2 (GLP-2), has been proposed as an agent that may enhance repair of damaged intestinal mucosa. The initial randomized controlled trial did not demonstrate a statistically significant benefit over placebo. In an open-labeled extension arm of the trial, half the patients achieved remission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727004\">",
"    <span class=\"h2\">",
"     Fish oil",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of proinflammatory cytokines are synthesized from n-6 fatty acids. An approach to reducing cytokine activity is the administration of fish oil using n-3 fatty acids. A meta-analysis of four studies of fish oil (with a total of 166 patients) found a non-statistically significant benefit for maintaining remission (RR 0.64, 95% CI 0.4-1.03) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/58\">",
"     58",
"    </a>",
"    ]. Subgroup analysis revealed a statistically significant benefit for enteric-coated capsules. However, two subsequent high-quality placebo-controlled trials (EPIC-1 and EPIC-2) involving a total of 783 patients with quiescent Crohn's disease found no benefit for prevention of relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/59\">",
"     59",
"    </a>",
"    ]. Thus, a benefit of fish oil in maintenance of remission of Crohn's disease appears to have been disproven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727011\">",
"    <span class=\"h2\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/36/19015?source=see_link\">",
"     Leflunomide",
"    </a>",
"    (Arava&reg;) is an isoxazole derivative approved by the United States Food and Drug Administration (FDA) for the treatment of rheumatoid arthritis (RA). It is structurally unrelated to other known immunomodulatory drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .) Clinical improvement was noted in 8 of 12 patients who were intolerant of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or 6-MP suggesting that further study in controlled trials is warranted [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727018\">",
"    <span class=\"h2\">",
"     Alequel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alequel is an extract of autologous colonic proteins from patients with Crohn's disease. The rationale for its use is based upon observations in animal models of IBD in which feeding autologous proteins prevented colitis. A pilot controlled trial in humans suggested possible clinical benefits, but none of the endpoints reached statistical significance on an intention-to-treat analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727025\">",
"    <span class=\"h2\">",
"     Low dose naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    , used at the very low dose of 4.5 mg nightly, was studied in Crohn's disease based on the idea that endogenous opioids and agonists may have a role in tissue repair as well as immunologic effects. A single center open label trial in active Crohn's disease suggested a significant benefit [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/62\">",
"     62",
"    </a>",
"    ]. In a subsequent randomized controlled trial in which 40 subjects with moderately to severely active Crohn&rsquo;s disease were randomized to receive naltrexone (4.5 mg daily) or placebo, 80 percent of patients treated with naltrexone had a 70 point decrease in Crohn's disease activity index score as compared with 40 percent in the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/63\">",
"     63",
"    </a>",
"    ]. Larger studies are needed before naltrexone can be recommended in patients with Crohn&rsquo;s disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18727142\">",
"    <span class=\"h2\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    is an immunosuppressive agent that is a structural analogue of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    . A pilot study in adults with moderate-to-severe Crohn's disease found no significant benefit compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or placebo for steroid-free remission at the end of three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/64\">",
"     64",
"    </a>",
"    ]. The study was underpowered and the rates of steroid-free remission were low overall (ie, 22 percent for everolimus, 38 percent for azathioprine, and 29 percent for placebo). Thus, its role is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393277\">",
"    <span class=\"h2\">",
"     Growth hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of regulatory peptides (such as growth hormone, and insulin-like growth factor I) are involved in the control of intestinal permeability, providing a rationale for clinical trials in Crohn's disease, which is associated with increased intestinal permeability.",
"   </p>",
"   <p>",
"    One study included 37 patients with moderately to severely active Crohn's disease who were randomly assigned to receive growth hormone (5 mg per day subcutaneously for one week followed by a maintenance dose of 1.5 mg per day) or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/65\">",
"     65",
"    </a>",
"    ]. All patients were also instructed to increase their dietary protein intake to at least 2 g per kilogram of body weight per day, since protein enhances the synthesis of endogenous intestinal protein. After four months, the mean Crohn's disease activity index decreased significantly more in patients receiving growth hormone (a decrease of 143 versus 19 points). Side effects included edema (observed in 10 patients) and headache (observed in five patients), which resolved within one month in most patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393284\">",
"    <span class=\"h2\">",
"     Immunostimulation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory bowel disease-like conditions observed in patients with certain immunodeficiency states (such as chronic granulomatous disease, glycogen storage disease Ib and Chediak-Higashi syndrome) suggest that a defect in immunity may have a role in the pathogenesis of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/66\">",
"     66",
"    </a>",
"    ]. These observations provided the rationale for clinical trials of human granulocyte colony stimulating factor (G-CSF) and human granulocyte-macrophage colony stimulating factor (GM-CSF) in patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a meta-analysis of three randomized trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/43/5814?source=see_link\">",
"     sargramostim",
"    </a>",
"    (GM-CSF) or placebo, there was no statistically significant difference in the proportion of patients who achieved clinical remission or had a clinical response (70 or 100 point reduction in Crohn's disease activity index) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/71\">",
"     71",
"    </a>",
"    ]. There was also no statistically significant difference in the proportion of patients who experienced serious adverse events although the incidence of bone pain, musculoskeletal chest pain, and dyspnea were higher in patients treated with sargramostim as compared to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393291\">",
"    <span class=\"h2\">",
"     Antituberculosis therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations have suggested a link between Crohn's disease and mycobacteria. It has been known for nearly a century that Crohn's disease resembles tuberculous gastroenteritis and is histopathologically similar to Johne's disease, an enteritis of ruminants caused by M. paratuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/72\">",
"     72",
"    </a>",
"    ]. In the late 1970s, Mycobacterium kansasii was cultured from the lymph nodes of a patient with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/73\">",
"     73",
"    </a>",
"    ]. More recently, M. paratuberculosis DNA has been detected in Crohn's disease tissue using PCR and in situ hybridization techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/74-78\">",
"     74-78",
"    </a>",
"    ], and antibodies to M. paratuberculosis have been detected in the serum of patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/74,79\">",
"     74,79",
"    </a>",
"    ]. In one study, M. paratuberculosis was cultured from the blood of 14 of 28 patients with Crohn's disease compared with only two of nine patients with ulcerative colitis and none of 15 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/80\">",
"     80",
"    </a>",
"    ]. Discordant data have also been published [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above provided a rationale for controlled trials of antituberculous therapy in patients with Crohn's disease. Several such trials have been published in final or preliminary form [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/82-89\">",
"     82-89",
"    </a>",
"    ], while others are ongoing. A meta-analysis of seven trials concluded that treatment may be helpful (pooled odds ratio 1.36, 95% CI 0.87 to 2.13) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/90\">",
"     90",
"    </a>",
"    ]. However, only a small number of patients had been studied. Furthermore, it is unclear whether the observed benefit was due to treatment of mycobacteria or to a nonspecific effect of the drugs, some of which have antibacterial effects on enteric flora. Another meta-analysis that included eight trials reached similar conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/91\">",
"     91",
"    </a>",
"    ]. A subsequent placebo-controlled trial involving 213 patients found no significant benefit at two years from combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/63/32760?source=see_link\">",
"     rifabutin",
"    </a>",
"    , and clofazimine [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/92\">",
"     92",
"    </a>",
"    ]. Despite these results, it remains unclear whether there are subsets of patients who might benefit from antituberculosis treatment. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=see_link\">",
"     \"Antibiotics for treatment of inflammatory bowel diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393298\">",
"    <span class=\"h2\">",
"     Parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease is relatively common in industrialized countries where colonization with intestinal helminths is uncommon. Helminths decrease immune responsiveness and reduce inflammation in animal models providing a rationale for trials in humans. Pilot open label studies have suggested that ingestion of the ova of Trichuris suis improved symptoms in patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/93\">",
"     93",
"    </a>",
"    ]. A pilot study suggested that another species, Necator americanus, may also be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/94\">",
"     94",
"    </a>",
"    ]. A controlled trial has nearly completed enrollment in Europe and a similar trial has been initiated in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393305\">",
"    <span class=\"h2\">",
"     Bone marrow transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case series have documented remission in some patients with severe, refractory Crohn's disease who have undergone hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/95-100\">",
"     95-100",
"    </a>",
"    ]. These observations suggest that host immune dysregulation has a role in the pathogenesis of Crohn's disease and that it can potentially be corrected. Similar benefits of HCT have been described for other autoimmune diseases. A randomized phase III clinical trial to evaluate the safety and efficacy of autologous stem cell transplantation (Autologous Stem Cell Transplantation for Crohn's Disease [ASTIC]) has been underway for a long time (",
"    <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00297193\">",
"     clinicaltrials.gov/ct2/show/NCT00297193",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393312\">",
"    <span class=\"h2\">",
"     Stem cell therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small phase I study of mesenchymal stem cells (MSC) in nine patients with refractory Crohn&rsquo;s disease demonstrated that administration of autologous bone marrow derived MSCs is safe and feasible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/101\">",
"     101",
"    </a>",
"    ]. This study led to the launch of multicenter, placebo-controlled studies. In another study of 10 patients with fistulizing Crohn&rsquo;s disease unresponsive to or unsuitable for medical treatment including biological agents or unsuccessfully treated by surgery, intrafistular MSC injections resulted in sustained complete fistula closure in seven patients and incomplete closure in three cases at 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/102\">",
"     102",
"    </a>",
"    ]. Other stem cell studies, including placenta-derived stem cells, are being initiated in Crohn&rsquo;s disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393319\">",
"    <span class=\"h2\">",
"     Leukopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of devices are being studied that remove a subset of leukocytes by passing a patient's blood through extracorporeal filters. The mechanism of action remains uncertain, as does the benefit. Adacolumn has been most extensively studied, primarily in ulcerative colitis, and is approved for the treatment of IBD in Japan. The studies have been open-labeled and, while the results appear promising, in a randomized control trial leukophoresis was not more effective in inducing clinical remission or response in patients with Crohn&rsquo;s disease as compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/103-106\">",
"     103-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393326\">",
"    <span class=\"h2\">",
"     Extracorporeal photopheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extracorporeal photopheresis (ECP) (approved for cutaneous T-cell lymphoma) uses 8-methoxypsoralen to treat leukocytes, which when exposed to ultraviolet light extracorporeally, induces apoptosis. In a pilot Phase II study of 28 patients refractory to or intolerant of immunosuppressants",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-TNF agents, 50 percent achieved a response (defined in this study as a decrease of 100 points in the Crohn's disease activity index) at three months [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393333\">",
"    <span class=\"h2\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Probiotics, the use of live bacteria as a therapeutic agent, continues to have numerous advocates, although demonstration of a clinical benefit in Crohn's disease has been lacking. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Studies for the treatment of active disease as well as prevention of recurrence after an operation have been negative. It remains uncertain whether the dose is too low, the bacteria chosen are not optimal, or the overall approach is fundamentally flawed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393340\">",
"    <span class=\"h2\">",
"     Prebiotics/complex carbohydrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;A pilot study of complex carbohydrates, fructo-oligosaccharides (FOS), not digested in the small bowel and metabolized by colonic bacteria suggested a benefit in Crohn's disease. These complex starches, derived from plants such as artichoke, are the preferred fuel of certain potentially beneficial bacteria, Bifidobacteria in particular. A brief, three-week open-label study suggested a biochemical and clinical benefit in patients with active disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/107\">",
"     107",
"    </a>",
"    ]. However, a randomized, double-blind, placebo-controlled trial in which patients with active Crohn&rsquo;s disease were randomized to 15 grams per day of FOS or a nonprebiotic placebo, there was no significant difference in clinical response or concentration of",
"    <em>",
"     Bifidobacteria",
"    </em>",
"    and",
"    <em>",
"     Faecalibacterium prausnitzii",
"    </em>",
"    at four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/34/17962/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4393347\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Advances in mucosal immunology reveal a broad set of targets to resolve the inflammation and symptoms of the disease. Many investigational treatments focus on inhibiting, suppressing or altering T-cell differentiation. Other investigational approaches focus on different aspects of the immune system. (See",
"      <a class=\"local\" href=\"#H4393207\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The intestinal mucosa persists in a state of controlled inflammation; proinflammatory cytokines (such as TNF-alpha, interleukin (IL)-1, IL-6, IL-8, and IL-12) are counterbalanced by antiinflammatory cytokines (such as IL-4, IL-10, IL-11, and IL-13). Inflammatory bowel disease represents a state of dysregulated inflammation. Drugs that can augment the antiinflammatory response have the potential to downregulate inflammation and thereby improve the disease. (See",
"      <a class=\"local\" href=\"#H4393214\">",
"       'Proinflammatory cytokine inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Adhesion molecules are involved in leukocyte migration and recruitment to sites of inflammation. Blockage of leukocyte migration has been proposed as a means of down-regulating inflammation.",
"      <strong>",
"      </strong>",
"      (See",
"      <a class=\"local\" href=\"#H4393242\">",
"       'Leukocyte adhesion inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other therapeutics under investigation take different theoretical approaches. Examples include the administration of growth hormone to regulate intestinal permeability, the use of helminths to restore T cell regulation, and the use of prebiotics to alter the gut flora. (See",
"      <a class=\"local\" href=\"#H4393270\">",
"       'Other'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/1\">",
"      Sandborn WJ, Feagan BG, Hanauer SB, et al. An engineered human antibody to TNF (CDP571) for active Crohn's disease: a randomized double-blind placebo-controlled trial. Gastroenterology 2001; 120:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/2\">",
"      Sandborn WJ, Feagan BG, Radford-Smith G, et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn's disease: a randomised, double blind, placebo controlled trial. Gut 2004; 53:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/3\">",
"      Feagan BG, Sandborn WJ, Baker JP, et al. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment Pharmacol Ther 2005; 21:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/4\">",
"      Hanauer S, Present D, Targan SR, et, al. CDP571, a humanized monoclonal antibody to TNFA, a well tolerated alternative in Crohn's disease patients who have experienced hypersensitivity reactions to infliximab (abstract). Gastroenterology 2003; :Abstract ID 106362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/5\">",
"      D'Haens G, Swijsen C, Noman M, et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. Am J Gastroenterol 2001; 96:2564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/6\">",
"      Sandborn WJ, Hanauer SB, Katz S, et al. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2001; 121:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/7\">",
"      Rutgeerts P, Lemmens L, Van Assche G, et al. Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open-label, pilot study. Aliment Pharmacol Ther 2003; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/8\">",
"      Rutgeerts P, Sandborn WJ, Fedorak RN, et al. Onercept for moderate-to-severe Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol 2006; 4:888.",
"     </a>",
"    </li>",
"    <li>",
"     Neovacs Announces Kinoid Trial Results. file://www.dddmag.com/news-Neovacs-Announces-Kinoid-Trial-Results-12810.aspx (Accessed on December 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/10\">",
"      Hommes D, van den Blink B, Plasse T, et al. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 2002; 122:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/11\">",
"      Dotan I, Rachmilewitz D, Schreiber S, et al. A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn's disease. Gut 2010; 59:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/12\">",
"      Vasiliauskas EA, Kam LY, Abreu-Martin MT, et al. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease. Gastroenterology 1999; 117:1278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/13\">",
"      Ehrenpreis ED, Kane SV, Cohen LB, et al. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 1999; 117:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/14\">",
"      Mansfield JC, Parkes M, Hawthorne AB, et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Aliment Pharmacol Ther 2007; 26:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/15\">",
"      Plamondon S, Ng SC, Kamm MA. Thalidomide in luminal and fistulizing Crohn's disease resistant to standard therapies. Aliment Pharmacol Ther 2007; 25:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/16\">",
"      Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2004; 351:2069.",
"     </a>",
"    </li>",
"    <li>",
"     18th United European Gastroenterology Week (UEGW) late breaking abstract. Panniccione R, Sandborn W, Gordon G, et al. Briakinumab (ABT874) for treatment of Crohn&rsquo;s disease. Abstract OP051D. Available at: www1.uegw10.uegf.org/guest/AbstractView?ABSID=11022 (Accessed on December 13, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/18\">",
"      Burakoff R, Barish CF, Riff D, et al. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm Bowel Dis 2006; 12:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/19\">",
"      Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology 2008; 135:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/20\">",
"      Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med 2012; 367:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/21\">",
"      Reinisch W, Hommes DW, Van Assche G, et al. A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn's disease. Gut 2006; 55:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/22\">",
"      Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis 2010; 16:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/23\">",
"      Yamamoto M, Yoshizaki K, Kishimoto T, Ito H. IL-6 is required for the development of Th1 cell-mediated murine colitis. J Immunol 2000; 164:4878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/24\">",
"      Atreya R, Mudter J, Finotto S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in crohn disease and experimental colitis in vivo. Nat Med 2000; 6:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/25\">",
"      Ito H, Takazoe M, Fukuda Y, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126:989.",
"     </a>",
"    </li>",
"    <li>",
"     Hueber W, Sands BE, Vandemeulebroecke M, et al. Inhibition of IL-17A by secukinumab is ineffective for Crohn's disease (CD) (abstract #10). Abstracts of the 6th Congress of the European Crohn's and Colitis Organisation, Dublin, Ireland 2011. Available at: file://www.ecco-ibd.eu/index.php/congress/8-6business-meetings/detail/46-5 (Accessed on January 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/27\">",
"      Autschbach F, Braunstein J, Helmke B, et al. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am J Pathol 1998; 153:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/28\">",
"      van Deventer SJ, Elson CO, Fedorak RN. Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease. Crohn's Disease Study Group. Gastroenterology 1997; 113:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/29\">",
"      Buruiana FE, Sol&agrave; I, Alonso-Coello P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2010; :CD005109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/30\">",
"      Schreiber S, Fedorak RN, Nielsen OH, et al. Safety and efficacy of recombinant human interleukin 10 in chronic active Crohn's disease. Crohn's Disease IL-10 Cooperative Study Group. Gastroenterology 2000; 119:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/31\">",
"      Fedorak RN, Gangl A, Elson CO, et al. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 2000; 119:1473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/32\">",
"      Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 2000; 289:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/33\">",
"      Braat H, Rottiers P, Hommes DW, et al. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin Gastroenterol Hepatol 2006; 4:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/34\">",
"      Vermeire S, Rutgeerts PJ, D'Haens GR, et al. A phase 2a randomized placebo-controlled double-blind multi-center dose escalation study to evaluate the safety, tolerability, pharmacodynamics and efficacy of AG011 in patients with moderately active ulcerative colitis (abstract #46). Gastroenterology 2010; 138 Suppl 1:S9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/35\">",
"      Du X, Williams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood 1997; 89:3897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/36\">",
"      Qiu BS, Pfeiffer CJ, Keith JC Jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996; 41:1625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/37\">",
"      Sands BE, Bank S, Sninsky CA, et al. Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohn's disease. Gastroenterology 1999; 117:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/38\">",
"      Sands BE, Winston B, Salzberg B, et al. A randomized, double-masked, placebo-controlled study of recombinant human interleukin eleven (RHIL-11) in Crohn's disease subjects not receiving prednisone (abstract). Gastroenterology 1999; 116:G3518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/39\">",
"      Herrlinger KR, Witthoeft T, Raedler A, et al. Randomized, double blind controlled trial of subcutaneous recombinant human interleukin-11 versus prednisolone in active Crohn's disease. Am J Gastroenterol 2006; 101:793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/40\">",
"      Hommes DW, Targan SR, Dignass A, et, al. Visilizumab therapy in subjects with moderate-to-severe, refractory Crohn's disease. Gastroenterology 2007; 132:A157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/41\">",
"      Abreu MT, Von Tirpitz C, Mannon PJ, et, al. Extracorporeal photoimmune therapy for refractory moderately active Crohn's disease: a multicenter, open-label study. Gastroenterology 2007; 132:A157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/42\">",
"      Baumgart DC, Lowder JN, Targan SR, et al. Transient cytokine-induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am J Gastroenterol 2009; 104:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/43\">",
"      Sandborn WJ, Colombel JF, Frankel M, et al. Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis. Gut 2010; 59:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/44\">",
"      Hanauer SB, Sandborn WJ, Sands BE, et al. A randomized placebo-controlled trial of abatacept for moderately-to-severely active Crohn's disease (CD) (abstract #649). Gastroenterology  2010; 138:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/45\">",
"      Askari FK, McDonnell WM. Antisense-oligonucleotide therapy. N Engl J Med 1996; 334:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/46\">",
"      Malizia G, Calabrese A, Cottone M, et al. Expression of leukocyte adhesion molecules by mucosal mononuclear phagocytes in inflammatory bowel disease. Gastroenterology 1991; 100:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/47\">",
"      Yacyshyn BR, Bowen-Yacyshyn MB, Jewell L, et al. A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. Gastroenterology 1998; 114:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/48\">",
"      Schreiber S, Nikolaus S, Malchow H, et al. Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohn's disease. Gastroenterology 2001; 120:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/49\">",
"      Yacyshyn B, Chey WY, Wedel MK, et al. A randomized, double-masked, placebo-controlled study of alicaforsen, an antisense inhibitor of intercellular adhesion molecule 1, for the treatment of subjects with active Crohn's disease. Clin Gastroenterol Hepatol 2007; 5:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/50\">",
"      Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn's disease. N Engl J Med 2003; 348:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/51\">",
"      Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol 2008; 6:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/52\">",
"      Feagan BG, Rutgeerts PJ, Sands BE, et al. Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial. Gastroenterology 2012; 142:S160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/53\">",
"      Hanauer S, Colombel JF, Feagan B, et al. Vedolizumab maintenance therapy for Crohn&rsquo;s disease: Results of GEMINI II, a randomized, placebo-controlled, double-blind, multi-center phase 3 trial. Am J Gastroenterol 2012; 107:S620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/54\">",
"      Feagan B, Rutgeerts P, Sands B, et al. Vedolizumab maintenance therapy for ulcerative colitis: Results of GEMINI I, a randomized, placebo-controlled, double-blind, multicenter phase 3 trial. Am J Gastroenterol 2012; 107:S609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/55\">",
"      Bekker P, Schreiber S, Keshav S, et, al. PROTECT-1, prospective randomized oral therapy evaluation of CCX282-B (TRAFICET-EN) in Crohn's disease. Gut 2007; 56:A23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/56\">",
"      Keshav S, Johnson D, Schall T, Bekker, P. Chemokine receptor antagonist CCX282-B (Traficet-En) maintained remission of Crohn&rsquo;s disease in PROTECT-1 study (abstract #647). Gastroenterology 2010; 138:S86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/57\">",
"      Buchman AL, Katz S, Fang JC, et al. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis 2010; 16:962.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/58\">",
"      Turner D, Zlotkin SH, Shah PS, Griffiths AM. Omega 3 fatty acids (fish oil) for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2007; :CD006320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/59\">",
"      Feagan BG, Sandborn WJ, Mittmann U, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 2008; 299:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/60\">",
"      Prajapati DN, Knox JF, Emmons J, et al. Leflunomide treatment of Crohn's disease patients intolerant to standard immunomodulator therapy. J Clin Gastroenterol 2003; 37:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/61\">",
"      Margalit M, Israeli E, Shibolet O, et al. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: a patient-tailored approach. Am J Gastroenterol 2006; 101:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/62\">",
"      Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 2007; 102:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/63\">",
"      Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: a randomized placebo-controlled trial. Dig Dis Sci 2011; 56:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/64\">",
"      Reinisch W, Pan&eacute;s J, L&eacute;mann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103:2284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/65\">",
"      Slonim AE, Bulone L, Damore MB, et al. A preliminary study of growth hormone therapy for Crohn's disease. N Engl J Med 2000; 342:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/66\">",
"      Korzenik JR, Dieckgraefe BK. Is Crohn's disease an immunodeficiency? A hypothesis suggesting possible early events in the pathogenesis of Crohn's disease. Dig Dis Sci 2000; 45:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/67\">",
"      Korzenik J, Pittler A, Diekgraefe B. Immunostimulation in Crohn's disease: retreatment and maintenance therapy with GM-CSF (abstract). Gastroenterology 2002; 122 (Suppl):A423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/68\">",
"      Korzenik JR, Dieckgraefe BK. An open-labelled study of granulocyte colony-stimulating factor in the treatment of active Crohn's disease. Aliment Pharmacol Ther 2005; 21:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/69\">",
"      Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. N Engl J Med 2005; 352:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/70\">",
"      Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 2002; 360:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/71\">",
"      Roth L, Macdonald JK, McDonald JW, Chande N. Sargramostim (GM-CSF) for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2011; :CD008538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/72\">",
"      Morgan KL. Johne's and Crohn's. Chronic inflammatory bowel diseases of infectious aetiology? Lancet 1987; 1:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/73\">",
"      Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 1978; 2:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/74\">",
"      Feller M, Huwiler K, Stephan R, et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect Dis 2007; 7:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/75\">",
"      Hulten K, El-Zimaity HM, Karttunen TJ, et al. Detection of Mycobacterium avium subspecies paratuberculosis in Crohn's diseased tissues by in situ hybridization. Am J Gastroenterol 2001; 96:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/76\">",
"      Sechi LA, Scanu AM, Molicotti P, et al. Detection and Isolation of Mycobacterium avium subspecies paratuberculosis from intestinal mucosal biopsies of patients with and without Crohn's disease in Sardinia. Am J Gastroenterol 2005; 100:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/77\">",
"      Autschbach F, Eisold S, Hinz U, et al. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 2005; 54:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/78\">",
"      Bentley RW, Keenan JI, Gearry RB, et al. Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. Am J Gastroenterol 2008; 103:1168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/79\">",
"      Suenaga K, Yokoyama Y, Nishimori I, et al. Serum antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig Dis Sci 1999; 44:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/80\">",
"      Naser SA, Ghobrial G, Romero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn's disease. Lancet 2004; 364:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/81\">",
"      Parrish NM, Radcliff RP, Brey BJ, et al. Absence of mycobacterium avium subsp. paratuberculosis in Crohn's patients. Inflamm Bowel Dis 2009; 15:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/82\">",
"      Lowry PW, Sandborn WJ, Lipsky JJ. Mycophenolate mofetil for Crohn's disease? Lancet 1999; 354:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/83\">",
"      Elliott PR, Burnham WR, Berghouse LM, et al. Sulphadoxine-pyrimethamine therapy in Crohn's disease. Digestion 1982; 23:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/84\">",
"      Graham DY, Al-Assi MT, Robinson M. Prolonged remission in Crohn's disease following therapy for Mycobacterium paratuberculosis infection (abstract). Gastroenterology 1995; 108:A826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/85\">",
"      Afdhal NH, Long A, Lennon J, et al. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig Dis Sci 1991; 36:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/86\">",
"      Kelleher D, O'Brien S, Weir DG. Preliminary trial of clofazimine in chronic inflammatory bowel disease (abstract). Gut 1982; 23:A449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/87\">",
"      Prantera C, Kohn A, Mangiarotti R, et al. Antimycobacterial therapy in Crohn's disease: results of a controlled, double-blind trial with a multiple antibiotic regimen. Am J Gastroenterol 1994; 89:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/88\">",
"      Shaffer JL, Hughes S, Linaker BD, et al. Controlled trial of rifampicin and ethambutol in Crohn's disease. Gut 1984; 25:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/89\">",
"      Swift GL, Srivastava ED, Stone R, et al. Controlled trial of anti-tuberculous chemotherapy for two years in Crohn's disease. Gut 1994; 35:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/90\">",
"      Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000; :CD000299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/91\">",
"      Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am J Gastroenterol 2000; 95:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/92\">",
"      Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 2007; 132:2313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/93\">",
"      Summers RW, Elliott DE, Urban JF Jr, et al. Trichuris suis therapy in Crohn's disease. Gut 2005; 54:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/94\">",
"      Croese J, O'neil J, Masson J, et al. A proof of concept study establishing Necator americanus in Crohn's patients and reservoir donors. Gut 2006; 55:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/95\">",
"      S&ouml;derholm JD, Malm C, Juliusson G, Sj&ouml;dahl R. Long-term endoscopic remission of crohn disease after autologous stem cell transplantation for acute myeloid leukaemia. Scand J Gastroenterol 2002; 37:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/96\">",
"      Kashyap A, Forman SJ. Autologous bone marrow transplantation for non-Hodgkin's lymphoma resulting in long-term remission of coincidental Crohn's disease. Br J Haematol 1998; 103:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/97\">",
"      Lopez-Cubero SO, Sullivan KM, McDonald GB. Course of Crohn's disease after allogeneic marrow transplantation. Gastroenterology 1998; 114:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/98\">",
"      Oyama Y, Craig RM, Traynor AE, et al. Autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease. Gastroenterology 2005; 128:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/99\">",
"      Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116:6123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/100\">",
"      Hasselblatt P, Drognitz K, Potthoff K, et al. Remission of refractory Crohn's disease by high-dose cyclophosphamide and autologous peripheral blood stem cell transplantation. Aliment Pharmacol Ther 2012; 36:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/101\">",
"      Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59:1662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/102\">",
"      Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/103\">",
"      Ayabe T, Ashida T, Taniguchi M, et al. A pilot study of centrifugal leukocyte apheresis for corticosteroid-resistant active ulcerative colitis. Intern Med 1997; 36:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/104\">",
"      Kawamura A, Saitoh M, Yonekawa M, et al. New technique of leukocytapheresis by the use of nonwoven polyester fiber filter for inflammatory bowel disease. Ther Apher 1999; 3:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/105\">",
"      Reinisch W, Nahavandi H, Santella R, et al. Extracorporeal photochemotherapy in patients with steroid-dependent Crohn's disease: a prospective pilot study. Aliment Pharmacol Ther 2001; 15:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/106\">",
"      Sands BE, Katz S, Wolf DC, et al. A randomised, double-blind, sham-controlled study of granulocyte/monocyte apheresis for moderate to severe Crohn's disease. Gut 2012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/107\">",
"      Lindsay JO, Whelan K, Stagg AJ, et al. Clinical, microbiological, and immunological effects of fructo-oligosaccharide in patients with Crohn's disease. Gut 2006; 55:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/34/17962/abstract/108\">",
"      Benjamin JL, Hedin CR, Koutsoumpas A, et al. Randomised, double-blind, placebo-controlled trial of fructo-oligosaccharides in active Crohn's disease. Gut 2011; 60:923.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4076 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17962=[""].join("\n");
var outline_f17_34_17962=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4393347\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4393207\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4393214\">",
"      PROINFLAMMATORY CYTOKINE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Anti-TNF therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - CDP571",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Etanercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Onercept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9385263\">",
"      - Other anti-TNF agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9385270\">",
"      Semapimod",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393221\">",
"      Thalidomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Anti-interleukin 12 and 23 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anti-interferon gamma antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Anti-interleukin 6 receptor monoclonal antibody (tocilizumab)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Anti-interleukin 17 antibodies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27729305\">",
"      Human recombinant immune-regulatory cytokines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Interleukin-10",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Interleukin-11",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18726171\">",
"      INHIBITORS OF T CELLS OR T CELL DIFFERENTIATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4393242\">",
"      LEUKOCYTE ADHESION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Antisense oligonucleotides",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Intercellular adhesion molecule-1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393249\">",
"      Anti-integrin antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4393256\">",
"      - Vedolizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4393270\">",
"      OTHER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727218\">",
"      Teduglutide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727004\">",
"      Fish oil",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727011\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727018\">",
"      Alequel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727025\">",
"      Low dose naltrexone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18727142\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393277\">",
"      Growth hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393284\">",
"      Immunostimulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393291\">",
"      Antituberculosis therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393298\">",
"      Parasites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393305\">",
"      Bone marrow transplantation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393312\">",
"      Stem cell therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393319\">",
"      Leukopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393326\">",
"      Extracorporeal photopheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393333\">",
"      Probiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4393340\">",
"      Prebiotics/complex carbohydrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4393347\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/34/20008?source=related_link\">",
"      Antibiotics for treatment of inflammatory bowel diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/23/31098?source=related_link\">",
"      Normal B and T lymphocyte development",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_34_17963="Types of shock";
var content_f17_34_17963=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73000&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Hemodynamic profiles of the types of shock",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Physiologic variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Preload",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pump function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Afterload",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tissue perfusion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Clinical measurement",
"       </td>",
"       <td class=\"subtitle2\">",
"        Pulmonary capillary wedge",
"pressure",
"       </td>",
"       <td class=\"subtitle2\">",
"        Cardiac output",
"       </td>",
"       <td class=\"subtitle2\">",
"        Systemic vascular resistance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mixed venous oxygen saturation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypovolemic",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cardiogenic",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Distributive",
"       </td>",
"       <td>",
"        &darr; or &harr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"       <td>",
"        &darr;",
"       </td>",
"       <td>",
"        &uarr;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17963=[""].join("\n");
var outline_f17_34_17963=null;
var title_f17_34_17964="Broad behavior screens I";
var content_f17_34_17964=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50139&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected broad-band behavioral screens-I",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Test/age range",
"       </td>",
"       <td class=\"subtitle1\">",
"        Purchasing information",
"       </td>",
"       <td class=\"subtitle1\">",
"        Time frame*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Ages and Stages Questionnaire: Social-Emotional (ASQ-SE)",
"         </strong>",
"        </p>",
"        <p>",
"         3 to 66 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Paul H. Brookes Publishing, Inc.",
"        </p>",
"        <p>",
"         P.O. Box 10624",
"        </p>",
"        <p>",
"         Baltimore, MD 21285",
"        </p>",
"        <p>",
"         Phone: 800.638.3775",
"        </p>",
"        <p>",
"         <a href=\"file://www.pbrookes.com\" target=\"_blank\">",
"          www.pbrookes.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $149 (includes reproducible questionnaires and users guide).",
"        </p>",
"       </td>",
"       <td>",
"        About 10 minutes (if interview needed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Brief-Infant-Toddler Social-Emotional Assessment (BITSEA) (2006)",
"         </strong>",
"        </p>",
"        <p>",
"         12 to 36 months",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pearson Assessments",
"        </p>",
"        <p>",
"         19500 Bulverde Road",
"        </p>",
"        <p>",
"         San Antonio, TX 78259",
"        </p>",
"        <p>",
"         Phone: 800.211.8378",
"        </p>",
"        <p>",
"         <a href=\"file://www.pearsonassessments.com\" target=\"_blank\">",
"          www.pearsonassessments.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $105 (includes manual, 25 BITSEA parent forms, and 25 BITSEA teacher forms).",
"        </p>",
"       </td>",
"       <td>",
"        About 6 minutes (if interview needed)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <p>",
"         <strong>",
"          Conners Rating Scale-Revised",
"         </strong>",
"        </p>",
"        <p>",
"         3 to 17 years",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Pearson Assessments",
"        </p>",
"        <p>",
"         Phone: 800.627.7271",
"        </p>",
"        <p>",
"         <a href=\"file://www.pearsonassessments.com\" target=\"_blank\">",
"          www.pearsonassessments.com",
"         </a>",
"        </p>",
"        <p>",
"         Cost of purchasing a specimen set: $276 (includes manual and 25 quick score forms of various versions).",
"        </p>",
"       </td>",
"       <td>",
"        About 20 minutes",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Does not include score time.",
"    </div>",
"    <div class=\"reference\">",
"     Frances Page Glascoe, 2011, Nolensville, TN: PEDSTest.com, LLC, www.pedstest.com. Adapted with permission.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17964=[""].join("\n");
var outline_f17_34_17964=null;
var title_f17_34_17965="PA catheter and survival";
var content_f17_34_17965=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F78324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F78324&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary artery catheterization has no effect on survival",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 425px; height: 258px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Kaplan-Meier survival curves to one year following high-risk surgery guided by pulmonary artery catheterization or standard perioperative management in almost 2000 patients. There was no difference in survival between the two groups.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data adapted from Sandham, JD, Hull, RD, Brant, RF, et al, N Engl J Med 2003; 348:5.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17965=[""].join("\n");
var outline_f17_34_17965=null;
var title_f17_34_17966="Auto PEEP trigger threshold";
var content_f17_34_17966=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F64640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F64640&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 501px\">",
"   <div class=\"ttl\">",
"    Trigger threshold for auto-PEEP",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 481px; height: 211px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Effect of auto-PEEP on elevation of the triggering threshold in a mechanically ventilated patient with obstructive airways disease. This graphic representation shows airway pressure over time; the solid blue line demonstrates the circuit pressure as measured by the ventilator manometer, and the dashed red line is the alveolar pressure. In the absence of auto-PEEP, the sensitivity setting of -1 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O would be achieved by the patient making inspiratory efforts at the end of expiration, when airway pressure is at its minimum. In the presence of auto-PEEP, alveolar pressure remains positive. In this setting, the patient's inspiratory effort needs to decrease airway pressure not only by the -1 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O sensitivity set on the machine, but also by the amount of positive alveolar pressure (auto-PEEP). In this graph, the patient's inspiratory efforts are insufficient to trigger the ventilator and the patient is \"locked out,\" being unable to get a breath because of an inability to overcome the elevated effective triggering threshold rendered by auto-PEEP.",
"    <div class=\"footnotes\">",
"     PEEP: positive end-expiratory pressure.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Puritan-Bennett 1994, Form AA-1888.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17966=[""].join("\n");
var outline_f17_34_17966=null;
var title_f17_34_17967="Platysmal bands";
var content_f17_34_17967=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F64918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F64918&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Platysmal bands on the neck",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 272px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vertical linear bands due to separation and protrusion of the platysma muscle are present on the anterior neck.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_34_17967=[""].join("\n");
var outline_f17_34_17967=null;
